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ABSTRACT 
 
Hyaluronic acid (HA) is a natural linear glycosaminoglycan that, thanks to its peculiar 
properties such as biocompatibility, resorbability and the possibility for an easy 
chemical functionalization, currently represents one of the most attractive building 
block for the preparation of advanced biomaterials for many biomedical applications. 
The overall aim of this thesis was to design, prepare and characterize advanced HA 
based systems for applications in regenerative medicine and drug delivery. 
However although HA is an excellent biomaterial, due to its hydrophilic nature, native 
HA is unsuitable to encapsulate hydrophobic drugs.  
Furthermore native HA exhibits physico-chemical properties incompatible to form 
stable structures to be used in vivo for regenerative medicine and drug delivery 
applications. Infact when HA is injected in physiological environment, it is subjected to 
a degradation process due to its high hydrophilicity and to the action of an enzyme 
known as hyaluronidase. 
For these reasons in this study in order to obtain HA stable nanostructures, able to 
incorporate  hydrophobic drugs, two strategies were developed. The first strategy was to 
realize nanostructured systems in which HA was anchored onto nanoparticles, based on 
hydrophobic polymers, containing drugs; the second strategy was to modify HA 
molecules with hydrophobic groups. Moreover to obtain a HA stable structure at 
macroscale for regenerative medicine application, HA molecules were modified by a 
crosslinking reaction. 
 
In particular in the first part of the thesis the design, the preparation and the 
characterization of HA-coated biodegradable nanoparticles (NPs) as new drug carriers 
for tumor targeting were reported. In particular the idea was to bind a HA shell to a 
biodegradable core (Polylactic-coglycolic acid (PLGA) particle) by means of a physical 
binding using an anphiphilic polymer, known as Pluronic ®,  that acts as a bridge 
between the hydrophobic PLGA and the hydrophilic HA. 
One of the most challenge in the design of nanoparticles is an efficient targeting. NPs 
can passively accumulate into tumors, taking advantage of enhanced permeation and 
retention (EPR) effect. However, NPs in vivo efficacy can be hampered by lack of cell 
internalization and/or by the fact that the loaded drugs may be released before 
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nanoparticles uptake. HA is an attractive material for tumor targeting delivery since it 
can specifically bind to the cancer cells overexpressing at their surface CD44, an HA 
binding receptor. Thanks to this specific interaction, HA binding to the tumor cells and 
its subsequently internalization are strongly enhanced. In light of this the HA based 
nanoparticles realized in this project can be efficiently internalized by the tumors cells 
by means of both a passive and an active targeting strategy.  
NPs were prepared by a single emulsion technique and characterized for their 
morphology, size, and surface charge. HA based nanoparticles shown a spherical shape 
and a size ranging from 170 to 300 nm. Bare PLGA particles shown immediate 
aggregation phenomena; HA addition allowed to obtain stable NPs size for more than 
10 days. Furthermore Irinotecan, a widely employed chemotherapeutic drug, was 
chosen to load NPs, and its in vitro release kinetics were assessed. The results 
demonstrated that nanoparticles were able to sustain Irinotecan release for at least 24 
days. 
 
The second part of the thesis deals with the development of amphiphilic hyaluronic acid 
derivative towards the design of micelles for the sustained delivery of hydrophobic 
drugs and for the viscosupplementation. The new syntetized amphiphilic HA derivative 
is an octenyl succinic anhydride (OSA) modified HA, obtained through a simple 
reaction in an aqueous medium involving exclusively HA hydroxyl groups. In this way 
it was possible to overcome the problems related to the HA modifications that involve 
carboxylic groups, which result in an alteration of the distribution of negative charges 
along the polymer backbone at physiological pH and probably affect fundamental 
biological and pharmacological HA properties. 
A morphological, dimensional, calorimetric and rheological studies of this novel HA 
derivatives were conducted. Furthermore the ability of this novel amphiphilic HA 
derivative to self-assemble into micelles and to act as a solubility enhancer and as a 
modulator of release kinetics of a hydrophobic anti-inflammatory drug was 
demonstrated. In particular from morphological analysis it resulted that micelles are 
spherical objects with diameters around 100 nm. Differential scanning calorimetric 
(DSC) analysis revealed that the ability of HA to sequester water seems to be enhanced 
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by the introduction of lipophilic functions within HA molecules, resulting in a further 
decrease of the fraction of free water able to freeze compared to the unmodified HA.  
Moreover in the perspective of using the novel OSA derivatives as 
viscosupplementation product, the rheological features assume a crucial role since they 
must properly restore the biomechanical functions of the normal synovial fluid. From a 
rheological point of view OSA-HA solutions appeared to be an appropriate tool to be 
used in viscosupplentation therapy owing to their suitable viscoelastic features; infact 
the OSA-HA solutions exhibit a rheological behavior similar to the human synovial 
fluid, that is viscous at low frequencies and prevalently elastic at high frequencies and 
characterized by the presence of crossover frequency.  
Concerning release studies, the results indicated that OSA-HA is able to self-assemble 
into micelles, load a hydrophobic drug and release the active molecule with controlled 
kinetics. In particular, the analysis of release profiles shown that drug diffusion into the 
gel is faster compared to gel/drug dissolution with the dissolution contribution 
becoming more and more relevant as the OSA-HA concentration increases. 
 
In the third part of this thesis the optimization and the characterization of  HA hydrogels 
for regenerative medicine were reported.  HA hydrogels, produced crosslinking HA 
molecules with divinyl sulfone (DVS) and based on a simple, reproducible and safe 
process that does not employ any organic solvents, were developed. Owing to an 
effective purification step, the resulting homogeneous hydrogels do not contain any 
detectable residual crosslinking agent and are easier to inject through a fine needle. 
HA hydrogels were characterized in terms of their viscoelastic and network structural 
properties. They exhibit a rheological behavior typical of a strong gel and show 
improved viscoelastic properties by increasing HA concentration and decreasing 
HA/DVS weight ratio. Furthermore it was demonstrated that processes such as 
sterilization and extrusion through clinical needles do not imply significant alteration of 
viscoelastic properties. Moreover  the crosslinks appear to compact the network, being a 
reduction of the mesh size by increasing the crosslinker amount. 
In vitro and in vivo HA hydrogel degradation tests demonstrated that these novel 
hydrogels show a good stability against enzymatic degradation, that increases by 
increasing HA concentration and decreasing HA/DVS weight ratio. 
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Finally the hydrogels show a good biocompatibility confirmed by in vitro and in vivo 
tests.  
 
In conclusion, HA coated nanoparticles composed of a hydrophilic shell and 
hydrophobic inner core were developed. These nano-sized particles could be suitable 
tools for applications in drug delivery and in particular for cancer therapy, taking 
advantage of  both passive accumulation in tumor tissues via the EPR effect and active 
targeting by the strong receptor-binding affinity of HA to CD44 receptor. 
Furthermore soft nanostructures, based on an amphiphilic HA derivative, were 
developed. These HA derivatives represent novel and promising biomaterials for the 
realization of systems able to self-assemble into micelles, sustain the delivery of an anti-
inflammatory hydrophobic drug, release the active molecule with a controlled kinetic 
and at the same time able to act as a viscosuplementation agent for the treatment of 
joints affected by osteoarthritis. 
Moreover HA crosslinked hydrogels were developed; these systems represent promising 
injectable biomaterials for application in regenerative medicine. 
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CHAPTER 1 
Introduction: Hyaluronic Acid 
 
In the last years increased attention has been paid on the use of hyaluronic acid or 
hyaluronan (HA) in the biomaterial field thanks to its peculiar properties such as 
biocompatibility, nonimmunogenicity, biodegradability and viscoelasticity. 
HA was discovered in 1934 by Karl Meyer and John Palmer in the vitreous humour of 
bovine eyes [1]. The name hyaluronic acid originates from hyaloid (vitreous) and 
uronic acid [2]. 
It is a linear polyanionic polymer composed of repeating disaccharide units of D-
glucuronic acid (GlcUA) and N-acetyl-D-glucosamine (GlcNAc), that are linked 
together throughalternating beta-1,3 and beta-1,4 glycosidic bonds.  
It belongs to the class of glycosaminoglycans (GAGs) and specifically it presents the 
most simple structure being the only one not covalently associated with a core protein 
and non-sulfated [3].  
HA is a primary component of the extra-cellular matrix of the mammalian connective 
tissues. It is an important structural element in the skin and is present in high 
concentration in the synovial joint fluids, vitreous humor of the eyes, hyaline cartilage, 
disc nucleus and umbilical cord [4-8]. 
HA plays a major role in several functions in vivo such as lubrification of arthritis 
joints, viscoelastic properties of soft tissues and it is involved in important cell functions 
such as cell motility, cell matrix adhesion and cell organization [9-13]. 
Thanks to its biocompatibility, physical, chemical properties and due to the ease of 
chemical functionalization, HA has generated increasing interest among researchers and 
it is already used in several biomedical applications [3-14] such as regenerative 
medicine and drug delivery.  
Herein an overview of the most important physical-chemical and structural properties of 
HA including some chemical modifications of the biopolymer to obtain HA derivatives 
Chapter 1: Introduction 
2 
 
was shown. Moreover some examples of applications in biomedical field (such as 
cosmetic surgery, ophthalmology, otolaryngology, orthopedic surgery, tissue 
engineering, drug delivery) were reported. 
 
 
1. 1 GENERAL FEATURES AND BIODISTRIBUTION 
 
1.1.1 Origin  
 
The HA production methods are based on extraction from animal sources or on 
microorganism fermentation. 
The traditional method for HA production is based on extraction from animal sources 
such as rooster comb; this procedure, however, is expensive and requires an extensive 
purification of the crude product [15-16]. Furthermore the use of animal-derived 
biomolecules for biopharmaceutical applications is facing growing opposition because 
of the risk of cross-species viral and other adventitious agent contaminations. 
For these reasons alternatives to the animal extraction of HA were gradually replacing 
by industrial techniques based on microorganism fermentation emerged in the 1990’s. 
In large industrial quantities, HA is produced by fermentation of strains of bacteria 
Streptococci such as Streptococcus equi, Streptococcus zooepidemicus, Streptococcus 
equisimilis, Streptococcus pyogenes and Streptococcus uberis. 
However Streptococcus requires an expensive and very difficult fermentation, the use of 
substantial volumes of organic solvents, and finally the HA product can contain endo- 
and exotoxins. 
The HA industrial manufacturing is recently devoted to the fermentation of Bacillus 
subtilis [6]. Bacillus subtilis represents a valid alternative to Streptococcus HA 
production because it is a non-pathogenic microorganism and the final HA product does 
not contain any endo- or exotoxins; moreover it’s possible to have a better control on 
HA molecular weight (MW) and also Bacillus subtilis grows on minimal media in 
contrast to Streptococcus that requires more expensive and complex media for growth. 
In this Ph.D. project, HA obtained by Bacillus subtilis fermentation and provided by 
Novozymes Biopolymer A/S, was used for its environmentally friendly production 
process and its ultra-purity. 
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1.1.2 Biodistribution and biological functions  
 
HA is widespread in nature having been found in vertebrate soft tissues such as joints, 
synovial fluid (SF), skin, vitreous humour of the eye, umbilical cords, roster combs 
[17], in algae [18], in mollusks [19], and also in cultured eukaryotic cell lines, and 
certain prokaryotes, where it occurs as a mucoid capsule surrounding the cell [16] (table 
1.1). 
In the human body the largest amount of HA (7-8 g of hyaluronate per average adult 
human, or approximately 50% of the total in the body) resides in the skin, where it is 
present in both the dermis and the epidermis (0.5 mg/g wet tissue). It’s well known that 
in a 70-kg individual there are around 15 g of hyaluronan, 5 g of which is turned over 
(degraded and synthesized) every day.  
 
Tissue or fluid 
Concentration 
(µg/ml) 
Rooster comb 7500 
Human umbilical cord 4100 
Human synovial fluid 1400-3600 
Bovine nasal cartilage 1200 
Human vitreous body 140-340 
Human dermis 200-500 
Human epidermis 100 
Rabbit brain 65 
Rabbit heart 27 
Human thoracic lymph 0.2-50 
Human urine 0.1-0.3 
Human plasma 0.01-0.1 
Table 1.1: HA occurrence in different animal tissues and fluids 
 
 
HA is involved in several functions in vivo. In the skin HA exhibits important structural 
and biological functions. As regards to the HA structural properties, it provides a matrix 
substrate for the distribution and organization of important molecules of the ECM such 
as  proteoglycans (PG), fibrin, fibronectin, collagen and elastin [20] (Figure 1.1). 
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Furthermore it maintains tissue hydration [21] thanks to its ability to retain water and 
also it ensures at the same time space and cohesion between the cells in the skin, 
allowing the diffusion of both nutrients and waste products [22]. 
 
 
Figure 1.1: Organization of proteoglycans and collagen in HA matrices 
http://www.glycoforum.gr.jp/science/hyaluronan/HA02/HA02E.html 
 
Moreover it was demonstrated that HA provides to the elimination of free radicals 
generated by the ultraviolet rays from sunlight. The ultraviolet light inflicts oxidative 
stress on cells and may damage their genetic material, thus causing degeneration and 
death. 
In cartilage, despite its relatively low content, HA functions as an important structural 
constituent of the matrix, forming an aggregation center for Aggrecan, a large 
chondroitin sulfate proteoglycan that retains its macromolecular assembly in the matrix 
due to specific HA–protein interactions [23].  
In the synovial fluid, there is an elevated concentration of high MW HA which serves 
as shock absorber and provides necessary lubrication for the joints, reducing friction of 
the moving bones and thus diminishing wear. Under inflammatory conditions, such as 
osteoarthritis or rheumatoid arthritis, high MW HA is degraded by reactive oxygen 
species (ROS), which reduces its viscosity and its lubricant and shock absorbing 
properties, leading to deteriorated joint movement and pain [24].  
HA is also involved in embryogenesis and is associated with cancer invasiveness and 
metastasis [25]. Moreover, HA has a wide MW, ranging from 1000 to 10,000,000 Da, 
and it playes different roles in the body depending on its MW. For example, high MW 
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HA, is space-filling, anti-angiogenic, and immunosuppressive, whereas the 
intermediate-sized polymers comprising 25–50 disaccharides are inflammatory, 
immunostimulatory, and highly angiogenic. Smaller HA oligosaccharides seem to 
function as endogenous danger signals. Some of the variably sized fragments trigger 
different signal transduction pathways [26]. 
HA is also known to play a role in promoting cell proliferation, differentiation and 
migration [27-28] by binding with cells with specific interactions. These processes 
infact  are mediated by proteins, known as hyaladherins,  that act as cellular receptors 
for HA. Examples of HA receptors are cluster determinant 44 (CD44) [29], receptor 
for hyaluronate-mediated motility (RHAMM) [30], HA receptor for endocytosis 
(HARE) [31-32], and lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) 
[33]) that can recognize and bind HA selectively. Within these receptors, CD44 and 
RHAMM have attracted much attention because they are involved in metastasis [34-
37]. In particular CD44 is the best characterized transmembrane HA receptor; it is 
expressed on the surface of several cells such as leucocytes, fibroblasts, keratinocytes 
and epithelial and endothelial cells [38], and it is also involved in different cellular 
processes (cell adhesion, migration, proliferation and activation as well as HA 
degradation and uptake) [39]. 
RHAMM was found on cell surfaces and also in the cytosol and nucleus [39]. It was 
demonstrated that it’s involved in regulating cellular response to growth factors and in 
cell migration, particularly for fibroblasts and smooth cells [40]. 
 
 
1.2  Physical and chemical properties of HA 
 
HA is a linear polysaccharide composed of repeating disaccharide unit of D-glucuronic 
acid  and N-acetyl-D-glucosamine, that are linked together through alternating b-1,4 
and b-1,3 glycosidic bonds [2, 41-42] (Figure 1.2). 
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Figure 1.2: Molecular structure of the HA repeating unit 
 
The number of repeating disaccharide units in a HA molecules can reach 10000 or 
more, that generates large molecules of up to several million daltons in weight and up 
to 10 μm in length. 
One of the main properties of HA, that makes this molecule attractive for several 
biomedical applications, is its capacity to retain water being a highly hydrophilic 
polymer [43]. In aqueous solution, due to the combination of different interactions (intra 
and intermolecular hydrogen bonding, hydrogen bonding with the solvent and 
intermolecular non-polar/hydrophobic interactions), HA exhibits preferred structures 
known as the primary, secondary and tertiary structures [44-46]. 
The primary structure is related to the sequence of HA disaccharide units. The 
secondary structure in HA solutions is due to the formation of intramolecular hydrogen 
bonding (including interaction between D-glucuronic acid and N-acetyl-D-
glucosamine and between two neighboring disaccharide units [24, 47-49]), and 
between the HA molecule and the solvent (Figure 1.3). 
 
Figure 1.3: Intramolecular hydrogen bonding and hydrogen bonding with the solvent in 
aqueous HA solutions. 
http://www.glycoforum.gr.jp/science/hyaluronan/HA02/HA02E.html 
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The sugar rings are relatively fixed in their shape; instead in correspondence of oxygen 
atom between two neighboring disaccharide units, it’s possible a rotation of 180 
degree. In particular each disaccharide unit could in principle rotate of 360 degree, but 
the configurations are limited by the presence of intramolecular hydrogen bonding and 
hydrogen bonding with the solvent. Due to this twist in the chains, the molecule 
assumes a two-fold helix structure (Figure 1.4). 
 
Figure 1.4:  Plan (1) and elevation (2) computer drawn projections of HA and view 
along the two-fold helix axis 
http://www.glycoforum.gr.jp/science/hyaluronan/HA02/HA02E.html 
 
Due to the presence of intermolecular nonpolar/hydrophobic interactions and 
intermolecular hydrogen bonding between neighboring HA chains, HA shows also a 
tertiary structure. Infact the axial hydrogen atoms of about 8 CH groups on the 
alternating sides of the secondary structure create secondary hydrophobic faces that 
energetically favor the formation a meshwork-like β -sheet tertiary structure as a result 
of molecular aggregation. The hydrophobic and hydrogen bonding interactions, 
countering electrostatic repulsion, allow HA molecules to aggregate leading to the 
formation of molecular networks (matrices) of HA. This structure is rigid and very 
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stable, even if it has some degree of flexibility and a large number of conformations are 
possible. It is also to be noticed that the tertiary structure of hyaluronan is sensitively 
dependent on the environment, it varies with pH and ionic strength, a behavior typical 
of a flexible polyelectrolytes. In particular it was demonstrated that HA chains contract 
with increasing ionic strength and decreasing pH [42]. 
Significative informations about the conformation of HA molecules in water can be 
obtained by dynamical mechanical analysis. This allows to obtain the viscoelastic 
properties of the materials by measuring the response of a sample when it is deformed 
under small periodic oscillation in shear [50]. 
Moreover the knowledge of HA solution viscoelastic properties allows to get 
informations on the solution structure thus giving the possibility to engineer the solution 
performance for the specific biomedical application. 
From this analysis it is possible to obtain the dependence of  the elastic modulus, G'(ω) 
and the viscous modulus G"(ω) upon frequency, the so called mechanical spectra. In 
particular G' gives information about the elasticity or the energy stored in the material 
during deformation, whereas G" describes the viscous character or the energy dissipated 
as heat.  
The ratio between the viscous modulus and the elastic modulus is expressed by the loss 
tangent: 
 
'
''
tan
G
G
=d                                                                                                           (1.1) 
 
where δ is the phase angle. The loss tangent is a measure of the ratio of energy lost to 
energy stored in the cyclic deformation. The phase angle, δ, is equal to 90° for a purely 
viscous material, 0° for a pure elastic material, and 0°< δ <90° for viscoelastic materials 
[51]. The information on the HA structural properties can be obtained by analyzing the 
mechanical spectra of HA solution [52]. 
HA based materials exhibit different viscoelastic properties. They can indeed behave as 
diluite solutions (Figure 1.5) or entangled  solutions (Figure 1.6) depending of the 
concentration and MW of HA. 
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Figure 1.5: Mechanical spectra of HA solutions at low molecular weight 
Low MW HA solutions [150 KDa] behave as diluite solutions as reported in figure 1.5. 
The mechanical spectra is characterized by a loss modulus greater than elastic modulus 
in all frequency range; these results suggest that no topological interaction, such as 
entanglement, occurs among HA chains, so HA molecules can flow as individual flow 
unit.  
Due to the expansion of HA random coil in water, the molecular weight increases also 
at low concentration leading to a different rheological behavior. Indeed even at low 
concentration high molecular weight solutions exhibit entangled network. 
The solution shows a viscous behaviour at low frequency (G’’>G’) and a prevalently 
elastic one at high frequencies (G’>G’’), as reported in Figure 1.6. The limit between 
the two regions is represented by the crossover frequency, usually expressed as ωc.   
This behaviour can be explained by considering that at low frequency entanglements 
among the chains occur and the molecular chains can release stress by disentanglement 
and molecular rearrangement during the period of oscillation, and hence, the solution 
shows viscous behavior (G’’>G’); instead at high frequency molecular chains cannot 
disentangle during this short period of oscillation, and therefore, they behave as a 
temporary cross-linked network, and the elastic behavior (G’ > G’’) is prevalent [5-6, 
53]. 
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Figure 1.6: Mechanical spectra of HA solutions at high molecular weight 
 
Moreover by increasing HA concentration, the viscoelasticity of the solutions increases 
[54-57]. The viscoelastic  properties of HA in aqueous solution are also influenced by 
the presence of small molecular agent [58-60]. For example, the presence of 
phospholipids, guanidine, and sodium chloride leads to decreases in both elastic and 
viscous moduli. The effect of these compounds on the viscoelasticity is due to the 
disruption of intermolecular interactions and reduction in the entanglement between HA 
molecules [61].  
 
 
1.3 Degradation  
 
1.3.1 Enzymatic degradation 
 
In physiological environment HA is subjected to a degradation process due to the action 
of three type enzymes, hyaluronidase (or hyase), b-d-glucuronidase, and β-N-acetyl-
hexosaminidase [62-63]. As regards to hyaluronidase, the degradation mechanism is 
based on the cleaving high molecular weight HA into smaller oligosaccharides. On the 
other hand b-d-glucuronidase, and β-N-acetyl-hexosaminidase further degrade the 
oligosaccharide fragments by removing nonreducing terminal sugars [39]. 
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Thanks to the hyaluronidase action, HA is used in combination with drugs to improve 
their dispersion and delivery. Infact hyaluronidase action allows to decrease the 
viscosity of HA, that is a component of interstitial barrier; in this way it’s possible to 
improve tissue permeability [64]. 
 
1.3.2 Ultrasonic degradation 
 
The treatment of HA by means of sonication causes HA degradation. In particular it was 
demonstrated that there is a linear relationship between the reaction time and the 
reciprocal of the square of HA molecular weight [65-68]. 
Furthermore HA high molecular weight chains appear to degrade more slowly than HA 
low molecular weight chains. It is important to underline that ultrasonic treatment does 
not allow complete degradation of HA in monomers, regardless ultrasonic energies and 
HA molecule type [69-70]. 
 
1.3.3 Ph-dependent and thermal degradation 
 
Temperature and pH are also factors that can imply degradation of HA. In particular it 
was demonstrated that at alkaline pH HA degrades randomly, because there is the 
cleaving of hydrogen bonding that takes part in structural organization of HA, resulting 
in a flexible random coil [71]. Furthermore HA solutions in acid media are subjected to 
degradation [72].  
Thermal degradation of HA solutions also occurs. It was proved that the viscosity 
decreases in function of time and exponentially in function of the temperature [73-74].  
 
 
1.4 HA derivatives  
 
Thanks to its above mentioned physical-chemical properties and to its large-scale 
production, in the last decades HA has been used in several applications. At the same 
time, however, the enlarged use of this biopolymer has led to consider some 
disadvantages such as its short in vivo residence time, due to the degradation catalyzed 
by hyaluronidase [75], and its poor mechanical properties. To overcome these 
drawbacks, various chemical modifications of the HA structure have been developed to 
synthesize new HA derivatives which are less susceptible to chemical and enzymatic 
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hydrolysis and show enhanced mechanical properties [76]. Chemical modifications of 
HA target three different functional groups: the primary and secondary hydroxyl groups, 
the glucuronic acid carboxylic group and the N-acetyl group (after deacetylation). 
Usually hydroxyls are modified through etherification, divynilsulfone crosslinking, 
esterification and bis-epoxide crosslinking, whereas carboxylates are modified by 
carbodiimide-mediated reactions, esterification and amidation. When modifying HA, it 
has to be taken into account that modifications carried on the -COOH can alter the HA 
biological behavior in the body because the carboxylic groups are the recognition sites 
for hyaluronidase and HA receptors [77]. For this reason, in many case low degree of 
modification are preferred to preserve the HA biological characteristic.  
HA can be modified through two main ways, conjugation or crosslinking; in the first 
case, a compound is grafted onto HA chain, whereas in the second case different HA 
chains are linked together (Figure 1.7). Crosslinked HA are also commonly referred to 
as hylans and can reach very high molecular weight (up to 23x106 Da) and prolonged in 
vivo residence time (1.5-9 days) [24, 78].  
 
 
Figure 1.7. Chemical conjugation (A) and chemical crosslinking (B) of a polymer 
 
To crosslink or conjugate HA polymers, numerous methods have been developed in 
organic solvents, such as dimethylformamide (DMF) or dimethylsulfoxide (DMSO). In 
this case, the native HA, which is in the form of a sodium salt, needs to be in its acidic 
form or a tetra-butylammonium salt (HA-TBA) for solubilization in organic solvents. 
However this requires additional steps of physical and chemical treatments that can 
induce HA chain hydrolysis [79-81]. 
Recently, a new appealing classification for HA derivatives has been proposed, it 
considers two different categories, “monolithic” and “living” HA derivatives [82-83]. 
The first arise when the chemical modification gives a final structure that cannot form 
A     B 
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new covalent bonds in the presence of cells or tissues and can only be pre-fabricated in 
different forms. On the contrary, living HA derivatives can be further modified or 
crosslinked in the presence of cells or tissues enabling a change in their physical form 
during in vivo or in vitro use. 
Figure 1.8 shows an hypothetical structure of an HA octasaccharide, containing some 
chemical modifications targeting the carboxylic acid or the primary hydroxyl group of 
the N- acetylglucosamine. Some of these modifications are monolithic, like the benzyl 
ester, the HYADD type amide, the divinyl sulfone (DVS) and the butane-1,4-diol 
diglycidyl ether (BDDE), while the others are examples of living HA derivatives. 
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Figure 1.8. An hypothetical HA octasaccharide showing some chemical modifications. 
 
Concerning the modification of the carboxylic group of the glucuronic acid, one of the 
most widely used reaction is the amidation [84-85], that usually need an activator agent. 
1-ethyl-3-[3-(dimethylamino)-propyl]-carbodiimide (EDC) is one of the preferred 
among the carbodiimide based activator agents because of its water solubility. EDC 
reacts with the HA carboxylic acid forming an O-acyl isourea-HA intermediate, which 
in turn react with the chosen amine to form the amide bond. However the O-acyl isourea 
intermediate is very reactive and can hydrolyze and then rearrange into a stable N-acyl 
urea by-product. In this regard, Bullpitt reported the use of N-hydroxsuccinimide (NHS) 
and 1-hydroxybenzotriazole (HOBt) with EDC to form a less hydrolyzable intermediate 
thus preventing the formation of the N-acylurea by-product [39]. One of main 
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advantages of the amidation using EDC is that it can be performed in water using the 
native HA. However, some authors have developed dimethyl sulfoxide (DMSO) 
methodologies on the acidic form of the HA to minimize the EDC hydrolysis thus 
reaching substitution degrees of up to 60-80% [39, 86].  Kuo et al. demonstrated that 
carbodiimides can also be used as the reagent, not only as the activator agent, and using 
biscarbodiimides managed to crosslink HA and form stable bis(N-acylurea) crosslinked 
gels [87]. Nonetheless, using dihydrazides, like the adipic hydrazide (ADH) no 
crosslinking was observed, but only single functionalization (Figure 1.8 for HA-ADH) 
[88]. 
EDC-hydrazide chemistry has also been to introduce thiol groups on the HA chain 
(Figure 1.8). This result was accomplished by EDC-mediated reaction of HA with 
disulfide containing dihydrazide, followed by reduction with dithiothreitol (DTT) [89].  
Amidation using CMPI (2-chloro-1-methylpyridinium iodide) as the activator agent is 
usually performed in DMF, thus HA have to be converted into the tetrabutylammonium 
salt (HA-TBA) through additional steps of preparation and purification [90]. With this 
method high degree of substitution up to 100% can be achieved, therefore it is higly 
effective. In addition, if no amine is added to the reaction medium, the CMPI-activated 
HA reacts with its own hydroxyl groups, forming an auto-crosslinked HA gel through 
ester crosslink between the HA chains [91]. These crosslinked HA products have been 
prepared by Fidia and are referred to as Auto Crosslinked Polysaccharide (ACP) gels. In 
gels of this kind, no bridge molecules are present, thus during their in vivo degradation, 
only natural components of HA are released [91]. 
The amidation of the -COOH of the glucuronic acid with alkylamides having long 
carbon chain (Figure 1.8) has also led to a class of amphiphilic HA amide derivatives 
called HYADD® and patented by Fidia [92]. 
A further chemical modification that involves carboxylic group is the esterification; 
this can be performed using epoxides, diazomethane or by alkylation using alkyl 
halides or tosylate activation. These reactions are usually performed in an organic 
solvent, such as DMF, on the TBA salt of HA. Among the ester derivatives of HA, 
HYAFF is particularly interesting. These are a class of hyaluronan derivative polymer, 
patented by Fidia, obtained by esterifying the free carboxyl group with different types 
of alcohol (aliphatic, aryliphatic, cycloaliphatic, and others). These derivatives are 
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characterized by a reduced hydrophilic character that results in a decreased solubility 
in water and slightly increased in the structural rigidity of the macromolecule, caused 
by the interaction of hydrophobic group organized in hydrophobic patches. The benzyl 
ester of hyaluronan (Figure 1.8), called HYAFF11®, has been well-characterized from 
both the chemical–physical and biological point of view [93]. It has been showed that 
the numerous hydrophobic benzyl groups along the polymeric chain are probably 
organized in hydrophobic patches. This gives the molecule a more rigid structure and 
reduces its ability to interact freely with water molecules. Amphiphilic ester 
derivatives have also been synthesized in which a rather small proportion of the 
carboxylic groups (~10% mol) was esterified by long alkyl chains (C12H25 or C18H37) 
[82]. In this case an alkyl halide (dodecyl or octadecyl bromide) reacts with the HA 
carboxylic groups, preliminarily transformed into its TBA salts to be solubilized in 
DMSO.  
For what concerns chemical modifications involving the -OH groups, one of the most 
common is the formation of ether using epoxides, DVS or ethylene sulfide. Among the 
epoxides, the most used is the BDDE (figure 1.8) which was patented for this reaction 
in 1986 by Malson and Lindqvist [94]. Nowadays BDDE is widely used for 
crosslinked HA hydrogels; the reaction consists of the epoxide ring opening to form 
ether bonds with the HA hydroxyl groups. Crosslinked HA hydrogels are also obtained 
using DVS, as reported in Figure 1.8, in this case, it has been demonstrated through 
histological assay that, even if the starting material is highly toxic, HA-DVS hydrogels 
are biocompatible [95].  
Thiol groups can be added to the HA chain not only by modifying the –COOH, as 
previously mentioned, but also through reaction at the hydroxyl group. Indeed, Serban, 
Yang and Prestwich have used ethylene sulfide to synthesize 2-thioethyl ether HA 
derivatives (Figure 1.8) performing the reaction at pH 10 overnight and at pH 8.5 for 
24 h after addiction of DTT.  
The –OHs can also be converted into esters by reaction with activated compounds. For 
example it is possible to graft acyl-chloride activated carboxylate compound onto the 
hydroxyl groups of HA by chloroacylation with thionyl chloride. This reaction is 
performed at room temperature in an organic solvent, such as DMSO. Thus it is also 
possible to graft poly(lactic acid) (PLA) oligomers to the HA chain by first convert the 
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HA to a more hydrophobic salt like the cetyltrimethyl-ammonium bromide (CTA) salt, 
which is easier to prepare than HA–TBA [96]. 
Methacrylated HA is another type of esterification of the –OH groups of HA (Figure 
1.8). It is usually performed using methacrylic anhydride in ice cold water for 12 h at 
pH 8–10. The obtained derivatives can be crosslinked by free-radical polymerization 
using UV-light (365nm) and a photo-initiator to obtain HA hydrogels.  
HA can also be modified by oxidation with sodium periodate of the hydroxyl groups of 
the glucuronic acid moiety of HA to dialdehydes, thereby opening the sugar ring. This 
derivative has been employed to graft peptides to the HA by reaction with the aldehyde 
groups [97], or to crosslink with HA–hydrazide derivatives [98]. 
Eventually, even the N-acetyl group of the N-acetyl glucosamine can be a modification 
site after deacetylation [99]. In this way an amino group is recovered that can then 
react with an acid using the same amidation methods described before. However 
deacetylation can induce chain fragmentation. Platt and Szoka mention the possibility 
of using enzymes for HA deacetylation, which was previously performed on the N-
acetylglucosamine moiety of heparin and heparan sulfate [100]. 
 
 
1.5 Applications 
 
In the last decades, HA thanks to its peculiar properties, exposed before, have attracted 
a great deal of attention and have been extensively used in several biomedical 
applications such as regenerative medicine and drug delivery (table 1.2).  
 
Biomedical Applications of HA HA role 
Viscosurgery Tissue protection and lubrification 
Tissue engineering 
Scaffold to mimic extracellular matrix 
environment for tissue regeneration 
Viscosupplementation Tissue fluid replacement or supplementation 
Viscoaugmentation Tissue filling and augmentation 
Drug delivery 
Biocompatible nanocarrier for the controlled 
release of therapeutic drugs and agents 
Table 1.2: Biomedical applications of HA based products 
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1.5.1 Ophthalmology  
 
HA is one of the major components of the eye tissues and in particular of the vitreous 
body [5]. It is commonly used in ophthalmology and in particular in cataract surgery as 
Ophtalmic Viscoelastic Device (OVD) due to its peculiar viscoelastic properties. It is 
injected in the eyes during the procedures of the opaque lens removal and substitution 
with an artificial lens. HA provides a barrier and acts as a shock absorber between the 
tissues and the tools in order to protect the delicate eyes tissues, and keeps the space 
during surgical manipulations. 
In general, an OVD requires specific rheological properties; it should be cohesive and 
have a high viscosity at low shear rates in order to maintain the space and to avoid 
ocular tissue collapse during the operation; on the other side it should be dispersive and 
have a viscosity which decreases rapidly with the deformation rate to ensure easy 
injection of OVD and adherence to tissues during the operation [101-103]. 
In order to fulfill the requirements for OVD as mentioned above, different strategies 
have been applied. Many products have been produced by varying molecular weight of 
the HA chain, obtaining OVD with cohesive or dispersive properties. Other OVD’s 
have been realized by the combination of HA with other polymers such as chondroitin 
sulfate (named Viscoat) or a new binary combination with hydroxypropylmethyl 
cellulose (HPMC, named VISC26) [104], which seems to represent the formulation that 
better fulfill the OVD requirements showing both cohesive and dispersive properties. 
In this case, the rheological synergy between HA and HPMC due to secondary 
interactions leads to a virtual increase of molecular weight and consequently high 
viscosity at low shear rate (cohesive properties), and at the same time it shows a 
decrease of viscosity at high shear rate due to the weakening of intermolecular 
interactions between the chains (dispersive properties).  
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1.5.2 Otolaryngology  
 
The vocal folds (VF) are composed of twin infoldings of mucous membrane stretched 
horizontally across the larynx. They vibrate, modulating the flow of air being expelled 
from the lungs during phonation [105-107]. 
HA is one of the main components of ECM [3, 10, 108-109] of VF and plays an 
important role in phonation process because it directly affects their viscosity. In fact the 
energy involved in the process of the phonation can be divided in: 1) the energy to 
initiate phonation, known as phonation threshold pressure (PTP), and 2) the energy to 
sustain phonation (Ep). Both energies strongly depend on viscosity of vocal folds tissue. 
In particular PTP can be expressed by: 
 
PTP = VDW/T                                                                                                           (1.2) 
 
where V is the mucosal wave velocity, D is the tissue damping coefficient (which is 
proportional to tissue viscosity), W is the prephonatory glottal width, and T is the 
thickness of vocal folds. Moreover Ep can be expressed by: 
 
Ep =(LT/D)η’ω2ξ 2                                                                                                     (1.3)                           
 
where L, T and D are the length, thickness and depth of the vocal folds, respectively, η’ 
is the tissue viscosity, ω is the angular frequency of oscillation and ξ is the vibrational 
amplitude [10, 110-111].  
The viscoelasticity of VF depends on the ability of HA chains to dissipate energy during 
the phonation process. For this reason HA based products have been used in VF 
augmentation. 
VF augmentation is used in therapy of scarring and paralysis of the vocal folds. During 
the phonation process the vocal folds are brought together near the centre of the larynx 
by muscle attached to the vocal folds basis. As air is forced through the vocal folds, they 
vibrate and produce sound. When vocal folds do not move well enough to be close to 
each other, a gap exists between them and the air leaks out too quickly thus causing the 
voice to sound breathy and weak. In this case to fill the gap, an augmentation substance 
is injected in the VF to achieve complete glottal closure. 
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However, the use of HA in VF augmentation is limited by its short residence time 
within vocal folds. In order to overcome this obstacle, derivatives of HA, obtained by 
chemically crosslinking the HA molecule, have been used as VF augmentation 
substances [112]. Furthermore it is seen that the HA based materials implies a durable 
tissue augmentation by attracting fibroblasts, which generated new collagen and ECM 
macromolecules [10, 113-114].  
 
1.5.3 Orthopedic surgery  
 
One of the main applications of HA is in the viscosupplementation of the joints affected 
by arthritis [115]. 
HA is present in high concentration in the ECM of joint tissues, including SF and the 
outer layer cartilage (figure 1.9) [116]. Thanks to its viscoelastic properties and its 
extraordinary capability to retain water, SF serves as lubricant and shock absorber [39, 
117]. 
 
 
 
Figure 1.9: Schematic representation of joint tissue including synovial fluid and outer 
layer cartilage, that are characterized by a high HA concentration 
 
When the joint is affected by osteoarthritis and rheumatoid arthritis there is a reduction 
of HA molecular weight [118-119] and concentration [120] in SF, which result in a 
decline in its viscoelastic properties [13]. The decrease of SF viscoelastic properties 
involves the degeneration of joints that become stiff and painful [7]. 
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The purpose of viscosupplementation by intra-articular injection of HA is to restore the 
rheological properties (viscosity and elasticity) of synovial fluids [121] by normalizing 
the concentration and molecular weight of HA [122]. Furthermore 
viscosupplementation not only allows restoring its mechanical properties, it has also 
been observed to allow an induction of the synthesis of high-molecular weight (HMW) 
HA by synoviocytes [123]. 
Currently, several viscosupplementation products based on HA are commercially 
available. Some of them are characterized by HA with low molecular weight 
(HYALGAN® and ARTZ®), or intermediate molecular weight (ORTHOVISC®) but 
lower than that of the hyaluronan in normal healthy synovial fluid, and other are made 
of cross-linked HA (HYLAN®, DUROLANE®, SYNVISC®) [124].  
Possible adverse events during the treatment of osteoarthritis by using HA based 
viscosupplementation products are joint infection, aseptic arthritis, and inflammation, 
even if in rare cases, being directly dependent upon the number of injections [125-127]. 
However, viscosupplementation with low MW HA preparations may have slightly 
higher risks and less benefits than viscosupplementation with high MW HA, because 
the relatively low MW HA preparations require more injections which may incur higher 
costs and chance of infection. 
Recently, a series of derivatives have been obtained via amidation of the polymer 
carboxyl groups by long chain alkyl amine [99]. This covalent anchoring of 
hydrophobic side chains onto the hydrophilic polysaccharides results in an amphiphilic 
derivative. These derivatives show the associative behavior in water characteristic of 
amphiphilic species [80] and, given their appropriate viscoelasticity, can be considered 
promising candidates for use in viscosupplementation [13].  
Moreover viscosupplementation products have shown their efficacy also in degenerative 
arthritis of the hip, ankle, shoulder and carpo-metacarpal joint of the thumb [128-141]. 
 
1.5.4 Tissue engineering  
 
HA is a versatile macromolecule that shows great potential for tissue engineering (TE) 
applications [142] because of its non-immunogenic properties [143-144], widespread 
availability, and ease of chain size manipulation. The inclusion of HA has created 
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biocompatible biomaterials and engineered tissues that can be degraded controllably and 
can facilitate angiogenesis, osteointegration, and cell phenotype preservation. 
HA is highly soluble in water and is quickly degraded in vivo by hyaluronidase; the 
short residence time of HA could be an obstacle to the structural integrity. In order to 
overcome this problem, different strategies have been used to stabilize HA as reported 
before, such as crosslinking or changes to the molecule chain of HA. Some of 
crosslinking methods include water-soluble carbodiimide crosslinking [145], polyvalent 
hydrazide crosslinking [146], DVS crosslinking [147], disulfide crosslinking [148], and 
photocrosslinking hydrogels through glycidyl methacrylate–HA conjugates [149]. 
As regards to the derivatives of HA, different esters and amides of HA have been used 
for tissue engineering approaches. For example a series of derivatives commonly used 
as polymeric scaffolds are HYAFF® obtained from esterification of the carboxyl groups 
of hyaluronic acid with different alcohol residue [80]. On the other side amides of HA, 
HYADD®, have been proved as bioactive and suitable vehicle to carry cells for tissue 
engineering procedures [150].  
In the tissue engineering field, HA and its derivatives have also been blended with other 
polymers such as polylactic-co-glycolic acid (PLGA) [151], polyethylene glycol (PEG) 
[152] and collagen.  
HA derivatives and their blends have been used as scaffolds for the regeneration of 
several tissues such as skin, cartilage, fibrocartilage, bone, intervertebral disc, adipose 
tissues, vascular tissues and heart valves. 
Because HA is present in high concentrations in the skin and has both structural and 
regulatory functions during the wound healing process [153], it has been considered as 
an appropriate candidate to support skin tissue regeneration. It was demonstrated that 
crosslinked HA hydrogel films accelerate the process of the wound healing [10]. It was 
proposed that it is possible due to creation of a hydrated and non-immunogenic 
environment, suitable for tissue repair. 
Moreover in skin tissue engineering to obtain epidermal and dermal-like tissues layers, 
three-dimensional scaffolds made up of benzyl esters of hyaluronan (HYAFF11®) and 
cultured in vitro with keratinocytes and fibroblasts, have been used [10, 154-155]. 
HYAFF11®, in the form of sponges, was proved to be effective in adipose tissue 
regeneration in a nude mouse model [156-158]. In particular, sponges with small and 
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large pore sizes were obtained using a salt leaching technique. A hydrophilic HA 
coating was added to the scaffold structure with the main aim to facilitate the process of 
cell (preadipocyte) seeding, through a fast medium absorption. The coating was realized 
by immersion of HYAFF11® sponges in an aqueous solution of HA biopolymer at a 
known concentration, and were subsequently freeze-dried [11]. 
For engineering fibro-cartilaginous tissues such as the central part of the meniscus, 
porous three dimensional composite scaffolds, based on HYAFF11® reinforced with 
polycaprolactone (PCL) [159], realized by phase separation technique and seeded with 
human chondrocytes, have been produced. 
HA derivatives have also been used as scaffolds for the regeneration of nucleus 
pulposus (NP) tissue engineering. In particular, a dodecylamide of HA, HYADD3®, has 
been proved as bioactive and suitable vehicle to carry cells for NP tissue engineering, 
while a crosslinked HA ester, HYAFF120®, showed interesting results if used as an 
injectable acellular material [160]. 
Benzyl derivatives of HA (Hyalograft® C and HYAFF11®) were also used as scaffolds 
for tissue engineering of cartilage [161]. It was demonstrated that cell seeded 
HYAFF11® scaffolds, when implanted in mice, develop into tissues resembling hyaline 
cartilage. It was noticed that both collagen type I and type II were present in the newly 
formed tissue even if collagen type I is considered a negative phenotypic marker, 
indicative of dedifferentiated chondrocytes. 
Recently, human clinical results for Hyalograft® C scaffolds have revealed more 
optimistic findings. It was reported that after implantation of the Hyalograft®, the grafts 
had integrated surrounding cartilage, and developed tissue in the locations of damaged 
tissues [162].   
 
1.5.5 Dermal fillers  
 
HA based dermal fillers (DF) in recent years aroused big interest in the area of cosmetic 
surgery for the rejuvenation of the dermis [4]. 
HA is an important structural element in the skin. Its concentration in the dermis 
decreases with the age promoting the formation of wrinkles [163]. With the use of DF it 
is possible to replace them, achieving a natural and younger appearance (Figure 1.10). 
Chapter 1: Introduction 
23 
 
There are several kinds of HA-based DF in commerce, but there is no ideal DF for all 
indications. They differ with regards to their physical and chemical properties, for 
example particle size, polymer concentration, density of cross-linking agents, viscosity, 
extrusion force, stress applied etc. HA based dermal fillers are usually based on 
bacterial fermented or rooster combs derived-HA, cross-linked with BDDE and thus 
have a HA concentration in the range 20-25 mg/ml. 
HA based DF differ significantly in their rheological properties depending on the site of 
the application. They can exhibit a behavior of strong gels, weak gels and entanglement 
network. 
 
Figure 1.10: Schematic representation of skin layers before and after DF injection 
 
Among the most used in commerce are Restylane, Perlane, Juvederm Voluma, Teosyal 
Deep Lines and Teosyal Ultra Deep which behave as strong gels; Belotero Basic, 
Belotero Intense, Juvederm Ultra 3 and Juvederm Ultra 4 behave as weak gels; Belotero 
Soft shows a mechanical spectrum that is typical of entanglement networks [164]. 
One of the most important aspects of the clinical use of DF is their persistence in the 
human body. The performance of dermal filler in vivo seems to be directly affect by 
materials physical properties. In particular the clinical data appear to correlate with the 
concentration of the polymer and with the product between the concentration and the 
percent elasticity, so these should be crucial parameters for the clinical performance of 
DF. 
 
 
1.5.6 Drug delivery  
 
Biological and chemical properties of HA qualify this macromolecule as a prospective 
carrier of drugs particularly for local application and/or targeting to lymphatic system 
[165]. Furthermore, it is immunologically inert and safely degraded in lysosomes of 
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many cells. HA can be conjugated directly to the drug or used to prepare nano- and 
micro-sized systems such as microcapsules, nano- and micro-particles and injectable 
devices for optimized drug delivery [166].   
HA has been extensively studied in ophthalmic [167-171], nasal [172] and parenteral 
drug delivery [173-178]. As vehicle for the controlled and localized delivery of active 
molecules, HA has been employed alone or in combination with natural polymers such 
as collagen [179], gelatin [180], chitosan [181] and synthetic polymers such as PLGA 
[182], poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) (PEO-
PPO-PEO).  
Thermosensitive and mucoadhesive polymeric platforms are potentially useful as 
vehicles for sustained delivery of proteins such as insulin or of topically active drugs in 
ophthalmology obtained by blending HA with poloxamers or pluronics [183-184]. 
Moreover the grafting of pluronic onto HA has been developed to be used for 
ophthalmic drug delivery systems (DDS). 
Recent studies demonstrated the promising potential of HA as a stable and effective 
nano-sized DDS for cancer treatment.  
Since HA has multiple functional groups available for chemical conjugation, several 
HA-drug conjugates have been developed as macromolecular chemotherapeutic 
prodrugs in which the conjugated drugs become active upon release from the HA 
backbone [88, 185-187]. In this case HA nanoparticles are formed by the self-assembly 
of the hydrophobically modified HA derivatives. 
Otherwise, HA has been chemically anchored onto various nanoparticles containing 
chemotherapeutic agents such as doxorubicin [188-189]. Infact HA shows a high 
affinity to tumor cells since it can specifically bind to the cancer cells overexpressing 
CD44 receptor.  
These systems exhibit prolonged circulation in blood and preferential accumulation at 
tumor tissues when they are systemically administrated in vivo [190-192]. This passive 
tumor targeting phenomenon of self-assembled HA nanoparticles, called the enhanced 
permeability and retention (EPR) effect, is attributed to the presence of leaky tumor 
vessels and the lack of an effective lymphatic drainage system in tumors [193-195].  
Moreover HA microspheres were reported to be promising also for the delivery of 
plasmid DNA and monoclonal antibodies in gene transfer [196].   
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THE Ph.D. PROJECT 
 
Objectives and challenges 
 
Hyaluronic acid (HA) currently represents one of the most attractive building block for 
the preparation of advanced biomaterials for many biomedical applications, as described 
in details in the introduction chapter. 
Therefore the overall objective of this thesis was to design and develop advanced HA 
based systems for applications in regenerative medicine and drug delivery. 
Although HA is an excellent biomaterial, HA native shows physico-chemical properties 
incompatible to form in vivo stable structures at macro and micro scale to use it for 
regenerative medicine and drug delivery. Infact when HA native is injected in 
physiological environment, a fast degradation process often occurs because from a side 
it has a high affinity for water molecules and from the other side it is degraded in vivo 
by hyaluronidase. For this reason, different strategies such as crosslinking or 
coniugation, have been developed to stabilize HA and obtain a material less susceptible 
to chemical and enzymatic hydrolysis, showing enhanced mechanical properties. 
However the modifications methods currently available to crosslink or conjugate HA 
molecules present some drawbacks. In particular some modifications involve HA 
carboxyl groups resulting in an alteration of the distribution of negative charges along 
the polymer backbone at physiological pH and probably affecting fundamental 
biological and pharmacological HA properties. Moreover another drawback is the use of 
organic solvent in the modification reaction that implies environmental issues, limits the 
upscalability of the preparation methods and often requires converting HA into its 
tetraalkylammonium salt or preparing reactive HA intermediates that makes more 
complex the preparation methods and often results in HA degradation. 
Furthermore native HA, because of its hydrophilic nature, is unsuitable for the 
encapsulation of hydrophobic drugs. In order to overcame this problem, in literature two 
strategies were adopted.  The first strategy, used to incapsulate hydrophobic drugs in 
HA based nano-sized drug carriers, was to realize nanostructured systems in which HA 
was anchored onto various nanoparticles, based on hydrophobic polymers, containing 
drugs. However HA was binded to the nanoparticles by means of a chemical reaction. 
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The second strategy was to modify HA molecules with hydrophobic groups, obtaining a 
more favourable starting material for the production of stable nanostructures and the 
durable encapsulation of hydrophobic drugs. 
However the current methods used for the preparation of amphiphilic HA involve 
modification to HA carboxyl groups and were developed in organic solvents. 
 
Part 1) 
Therefore the aim of the first part of this work was to formulate HA-coated 
biodegradable nanoparticles for the intracellular targeting of chemotherapeutic(s).  
In particular the idea was to bind the HA shell to a biodegradable core (Polylactic-
coglycolic acid (PLGA) particle) by means of a physical binding using an amphiphilic 
polymer that acts as a bridge between the hydrophobic PLGA and the hydrophilic HA. 
In this way it was possible to obtain nanocarriers in a simple way avoiding the problems 
related to a chemical reaction as mentioned before. 
Furthermore one of the most challenge in the design of nanoparticles is an efficient 
targeting. Nanoparticles can passively accumulate into tumors, taking advantage of 
enhanced permeation and retention (EPR) effect. However, nanoparticle in vivo efficacy 
can be hampered by lack of cell internalization and/or by the fact that the loaded drugs 
may be released before nanoparticles uptake. To overcome these limitations in recent 
years the research has been devoted to the preparation of nanoparticles functionalized 
with antibodies, nucleic acids, proteins, and various ligands, such that they can bind in a 
specific way to the tumor cells, and can be internalized by means of receptor-mediated 
endocytosis. Of the different ligands studied, antibody fragments have been extensively 
used for nanoparticles funzionalization. However, the use of antibodies for therapeutic 
purposes suffers from their sometimes potent immunogenicity and as a consequence the 
binding affinity for the target is often deteriorated.  
It is well known that HA is an attractive material for tumor targeting delivery since it 
can specifically bind to the cancer cells overexpressing at their surface CD44, an HA 
binding receptor. Thanks to this specific interaction, HA binding to the tumor cells and 
its subsequently internalization are strongly enhanced.  
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In light of this the HA based nanoparticles realized in this project can be efficiently 
internalized by the tumors cells by means of both a passive and an active targeting 
strategy. 
Furthermore another important challenge in the design of nanopaticles for drug delivery 
is the particles aggregation. PLGA is the mainly polymer used in drug delivery for its 
peculiar properties of biocompatibility and biodegradability, but nanoparticles of 
PLGA, besides the fact that had no targeting groups for specific tumor cells, often are 
subjected to a phenomenon of aggregation. The idea to create a HA shell around the 
biodegradable core of nanoparticle, allows to improve the nanoparticles dimensional 
stability, taking advantage of electrostatic repulsion due to the negative charge of HA. 
 
 
Part 2) 
 
The aim of the second part of  this work was to design a delivery system based on an 
amphiphilic HA derivative able to self-assemble into micelles, load a hydrophobic drug 
and release the active molecule in situ with controlled kinetics. The novel syntetized 
amphiphilic HA derivative is an octenyl succinic anhydride (OSA) modified HA, 
obtained through a simple reaction in an aqueous medium, and which involves 
exclusively HA hydroxyl groups, overcoming the problems mentioned before. In 
particular theses derivatives present great potential since, firstly no organic solvents are 
used in the reaction, thus avoiding environmental issues and allowing the upscalability 
of the preparation method; secondly, the reaction does not involve HA carboxyl groups 
which can neutralize negative charges along the polymer backbone. Actually, it is 
important to maintain the charge distribution that can confer an electrostatically-induced 
stability in the perspective of using the self-assembling properties of these derivatives 
toward the design of micelles for the drug delivery of poorly soluble drugs. 
Furthermore the idea of this work was also to combine a local/controlled delivery of a 
hydrophobic anti-inflammatory drug and HA viscosupplementation.  
Intra-articular injection of HA (viscosupplementation) is one of the most used therapies 
for the treatment of knee osteoarthritis and  its goal is to restore the elastic and viscous 
properties of the synovial fluid (SF). Pathologic alterations occurring in joint diseases, 
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indeed, lead to a decrease in SF of HA molecular weight and concentration, and 
consequently a decline in SF viscoelastic properties. The beneficial improvements in SF 
viscoelastic properties and joint functions derive from both the intrinsic viscoelastic 
properties of HA and its potential stimulatory effect on the synthesis of high molecular 
weight HA by synoviocytes. 
Moreover, to stimulate the production of healthy HA and facilitate the homeostasis in 
the joint region, oral administration of anti-inflammatory drugs is often necessary in 
combination, or as an alternative to HA viscosupplementation. However, the prolonged 
use of such drugs can cause important systemic adverse effects and, therefore, intra-
articular injections of anti-inflammatory drug/s are often practiced.  
So the idea of this study was to design a delivery system able to prolong the release of 
an anti-inflammatory drug into the joint cavity and, at the same time, able to restore the 
viscoelastic features of pathologic SF. 
 
Part 3) 
 
The aim of the third part of this work was to produce stable structures at macroscale 
obtained crosslinking HA molecules to form injectable hydrogels for regenerative 
applications. 
The design of HA hydrogels requires to consider many parameters such as HA source, 
HA concentration, buffer environment for the hydrogel, nature of the crosslinking 
agent, crosslinking agent/HA weight ratio. However, regardless of these elements, the 
purity of the HA raw material and the safety of the crosslinking technology are crucial 
elements in achieving a hydrogel that can be safely administered to patients. 
For these reasons in this work HA produced by fermentation of the novel, superior and 
safe strain, namely Bacillus subtilis, has been used to produce hydrogels. This 
production technology affords a HA product with unique advantageous properties such 
as reproducible molecular weight. In addition, the higher purity of Bacillus-subtilis 
derived HA compared to the available sources of HA offers the possibility of heat 
sterilization with minor degradation under given conditions and allows its use with 
various ingredients without degradation or decrease in viscosity.  
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Moreover the hydrogels were obtained by means of a crosslinking reaction with 
divinyl sulfone (DVS) that involves hydroxyl groups of HA molecular backbone, 
avoiding the problems related to the modification reactions involving HA carboxyl 
groups.  
The hydrogels were produced with on a simple, reproducible and safe process that 
does not employ any organic solvents. Owing to an effective purification step, the 
resulting homogeneous hydrogels do not contain any detectable residual crosslinking 
agent.  
Moreover the injectability of the hydrogel through pharmaceutical needles is a 
fundamental property to consider in the design of hydrogel to be used in regenerative 
medicine. In particular it’s important to optimize gel preparation to obtain a material 
with tailored properties, i.e. a good injectability profile while maintaining the 
mechanical properties.  
So in this frame the aim was to produce cross-linked HA hydrogels with improved 
properties, such as higher homogeneity and increased softness compared to the 
standard DVS crosslinked HA-hydrogels and an easier syringeability. 
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CHAPTER 2 
 
Hyaluronic Acid-Coated Biodegradable Nanoparticles: 
Preparation, Characterization and Preliminary 
Assesment as New Drug Carriers For Tumor 
Targeting 
 
ABSTRACT 
Nanoparticles (NPs) can passively accumulate into tumors, taking advantage of 
enhanced permeation and retention (EPR) effect. However, NPs in vivo efficacy can be 
hampered by lack of cell internalization and/or by the fact that the loaded drugs may be 
released before NPs uptake. Hyaluronic acid (HA) is attractive for tumor-targeted 
delivery since it can specifically bind to the cancer cells overexpressing CD44 
receptor. For these reasons HA based NPs can be efficiently internalized by cells by 
means of both a passive and an active mechanism. 
In this context, the aim of this work was to formulate HA-coated biodegradable NPs 
for the intracellular targeting of chemotherapeutic(s). In particular, NPs made of 
poloxamers and polylactic-coglycolic acid (PLGA) blends were coated with HA by a 
single emulsion technique. NPs were characterized for their size, morphology and zeta 
potential.  
 
2.1 INTRODUCTION 
 
In the last years NPs have attracted great interest in the field of cancer therapy [1-3] 
thanks to their ability to encapsulate a quantity of poorly water-soluble anticancer drugs 
and release them in a sustained manner at target site; in this way from a side they can 
enhance the intracellular concentration of drugs in cancer cells and from other side they 
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allow to avoid toxicity in normal cells, overcoming the lack of specificity of 
conventional chemotherapeutic therapy [4-7] (figure 2.1). 
 
 
Figure 2.1: Schematic representation of drug absorption through biological membrane 
in the case of free drug and in the case of nanoparticles 
 
Kumaresh S. Soppimath, Tejraj M. Aminabhavi, Anandro R. kulkarni, Walter E. Rudzinski. 
“Biodegradable polymeric nanoparticles as drug delivery devices”. Journal of Controlled Release 
2001. Vol. 70: 1-20. 
 
Furthermore, NPs can accumulate into tumor cells and tissues by taking advantage of 
passive and/or active targeting [8-11]. The passive tumor targeting phenomenon of NPs 
is known as the enhanced permeability and retention (EPR) effect, that is the property 
by which NPs tend to accumulate in tumor tissue much more than they do in normal 
tissues (figure 2.2).  
The general explanation that is given for this phenomenon is that, in order for tumor 
cells to grow quickly, they must stimulate the production of blood vessels. The newly 
formed tumor vessels are usually abnormal in form and architecture (leaky, non-
organized and hyperpermeable). So nanoparticles can passively accumulate at target 
sites and a preferential extravasation of circulating nanoparticles occurs [12-19].  
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Figure 2.2: Passive targeting strategy of NPs, enhanced permeability and retention 
(EPR) effect 
Nanomedicine, Future science group (2010) 
 
However, this passive targeting strategy of NPs is limited by the possible lack of cell 
internalization and/or by the release of the loaded drugs before NPs uptake [20]. To 
overcome these limitations in recent years the research has been devoted to the 
preparation of NPs functionalized with antibodies [21-23], nucleic acids [24-25], 
proteins [26-29], and various ligands [30-32]. Functionalized NPs can recognize and 
bind in a specific way to the tumor cells, and they can be internalized by means of 
receptor-mediated endocytosis [33-35]. 
 Of the different ligands studied, antibody fragments have been extensively used for NPs 
funzionalization. However, the use of antibodies for therapeutic purposes suffers from 
their sometimes potent immunogenicity and as a consequence  the binding affinity for 
the target is often deteriorated [36].  
HA is a naturally occurring polysaccharide composed of repeating disaccharides of D-
glucuronic acid and N-acetyl-D-glucosamine and mainly present in the extra-cellular 
matrix of the mammalian connective tissues [37-41]. It is an important structural 
element in the skin and is present in high concentration in the synovial joint fluids, 
vitreous humor of the eyes, hyaline cartilage, disc nucleus and umbilical cord [42-46]. 
HA plays a major role in several functions in vivo such as lubrification of arthritis 
joints, viscoelastic properties of soft tissues and it is involved in important cell functions 
such as cell motility, cell matrix adhesion and cell organization [47-51]. Thanks to its 
excellent biocompatibility, biodegradability, unique physical, chemical and biological 
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properties and to the ease of chemical functionalisation, HA has generated increasing 
interest among researchers and it is already used in several biomedical applications such 
as regenerative medicine [52] and drug delivery [53-57].  
In particular HA is an attractive material for tumor-targeted delivery since it can 
specifically bind to the cancer cells overexpressing CD44 receptor [58-61]. In this way 
NPs enter the tumor through the leaky microvascolature of tumors, HA binds to CD44 
cell receptors and conseguently there is a co-internalization of HA and drug leading to 
an increased intracellular drug release (figure 2.3). 
 
 
Figure 2.3: Active targeting strategy of NPs  
 
Several HA-based drug carriers have been studied for tumor targeting. Since HA has 
multiple functional groups available for chemical conjugation, several HA-drug 
conjugates have been developed as macromolecular prodrugs in which the conjugated 
drugs become active upon release from the backbone of HA [62-65]. 
Otherwise, HA has been chemically anchored onto various nanoparticles containing 
drugs [66-72]. For example PLGA-grafted HA copolymers were synthesized and 
utilized as target specific micelle carriers for Doxorubicin. For grafting hydrophobic 
PLGA chains onto the backbone of hydrophilic HA, HA was solubilized in an 
anhydrous DMSO by nano-complexing with dimethoxy-PEG. The carboxylic groups of 
HA were chemically grafted with PLGA, producing HA-g-PLGA copolymers. 
Resultant HA-g-PLGA self-assembled in aqueous solution to form multi-cored micellar 
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aggregates and Doxorubicin was encapsulated during the self-assembly [73] (figure 
2.4). 
 
 
Figure 2.4: HA-g-PLGA self-assembled in aqueous solution to form multi-cored 
micellar aggregates and Doxorubin was encapsulated during the self-assembly. 
 
Hyukjin Lee, Cheol-Hee Ahn, Tae Gwan ParkPoly[lactic-co-(glycolic acid)]-Grafted Hyaluronic Acid 
Copolymer Micelle Nanoparticles for Target-Specific Delivery of DoxorubicinMacromol. Biosci. 2009, 9, 
336–342 
 
These HA modified macromolecular prodrugs and nano-sized drug carriers exhibited 
enhanced tumor targeting ability and therapeutic efficacy, compared to free anticancer 
agents. It has been reported that the pharmacokinetics of drug conjugates and 
nanoparticles are determined by their physicochemical properties such as surface 
chemistry, size, surface charge, and molecular weight [74-75]. 
However HA modified macromolecular prodrugs and nano-sized drug carriers were 
obtained by means of a chemical reaction.  
In this context, the aim of this work was to formulate HA-coated biodegradable NPs 
for the intracellular targeting of chemotherapeutic(s).  
PLGA is the mainly polymer used in drug delivery for its peculiar properties of 
biocompatibility and biodegradability. However NPs of PLGA had no targeting groups 
for specific tumor cells and also a phenomenon of aggregation often occurs. In order to 
overcome this problem, the idea was to create a HA shell around the biodegradable 
core of NP in order to improve the PLGA NPs dimensional stability taking advantage 
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of the negative charge of HA that implies a electrostatic repulsion between the NPs. 
Furthermore HA shell was binded to the biodegradable core by means of a physical 
binding using an anphiphilic polymer that acts as a bridge between the hydrophobic 
PLGA and the hydrophilic HA (figure 2.5). In this way it was possible to obtain a 
stable drug carrier in a simple way avoiding the problems related to a chemical 
reaction. 
 
Figure 2.5: Schematic representation of the nanoparticles characterized by HA 
shell, biodegradable core and poloxamers that act as bridge between PLGA 
particles and HA 
 
In particular NPs made of poloxamers and PLGA blends were coated with HA by a 
single emulsion technique. NPs were characterized for their size, morphology and zeta 
potential.  
 
2.2 MATERIALS AND METHODS 
 
2.2.1 Materials  
 
Hyaluronic acid (HA) with a weight-average molecular weight (MW) of 850,000 Da 
was provided by Novozymes Biopharma (Denmark). Poly(lactic-co-glycolic acid) 
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(PLGA) (RG504H, MW 12,000 Da) was purchased from Boherniger Ingelheim 
(Germany).  
Poloxamers (PEOa-PPOb-PEOa), a group of amphiphilic triblock polymers, designed 
with variable numbers of oxyethylene (a) and oxypropylene (b) units, were employed. 
In particular in this study, poloxamer F127 (a=100 and b=65) and F68 (a=76 and 
b=29), obtained from Lutrol (Basf, Germany), were used. 
Phosphate buffer saline (PBS) tablets without calcium and magnesium were obtained 
from MP Biomedicals Inc. (France). 
 
2.2.2 Nanoparticles preparation 
 
NPs were prepared by a single emulsion technique (oil in water). In order to obtain 
NPs suitable for biomedical applications, formulations with different amount of HA, 
poloxamers, and PLGA were prepared. 
In table 2.1 all the formulations prepared were reported: 
-NPs characterized by PLGA and poloxamers, indicated with  PP, at different polymers 
concentrations (2, 4, 6% w/v) (PP2, PP4, PP6); 
- NPs characterized by PLGA, poloxamers, HA,  indicated with PP HA, with a constant 
amount of HA (30 mg) and at different polymers concentrations in the organic phase (2, 
4, 6% w/v), (PP2-HA30, PP4-HA30, PP6-HA30); 
- NPs characterized by PLGA, poloxamers, HA at the same concentration of polymers 
in the organic phase (2% w/v) and different amounts of HA (6, 30, 60 mg) (PP2-HA6, 
PP2-HA30, PP2-HA60); 
- NPs characterized by PLGA, poloxamers, HA at different concentrations of 
poloxamers (0, 0.5, 1% w/v) in the water phase.  
Briefly, solutions of PLGA and poloxamers (F127 and F68 1:1 w/w) in acetone, at 
different polymer concentrations and keeping constant PLGA-poloxamers weight ratio, 
were prepared. The organic phase was emulsified by vortexing for 5 min with the 
aqueous phase containing different HA and poloxamers amounts. The resulting 
emulsion was sonicated for 4 min at 4°C using a Branson Ultrasonic Cleaners (Model 
3510) and the solvent was evaporated at 35°C for 35 minutes by using a device called 
a rotary evaporator (Laborota 4010 digital, HEIDOLPH).  
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A solution of sucrose, that acts as a cryoprotectant,  prepared by mixing 600 mg of 
sucrose in 9 ml of bidistilled water was added to the NPs suspension.  
Nanoparticles were finally separated from supernatant by centrifugation at 13000 rpm 
for 60 minutes and lyophilized (Heto PowerDry PL6000 Freeze Dryer, Thermo 
Electron Corp., USA; -50 °C, 0.73 hPa) for 24 h. 
 
 
Formulations 
 
 
 
Oil phase Water phase 
PLGA  
(mg)  
F68  
(mg)  
F127  
(mg)  
C
3
H
6
O  
(ml)  
Polymer 
concentration 
in the organic 
phase, % 
(w/v) 
HA  
(mg)  
F68  
(ml)  
F127  
(ml)  
DDW  
(ml)  
PP2  10  5  5  1  2  -  -  -  6  
PP4  20  10  10  1  4  -  -  -  6  
PP6  30  15  15  1  6  -  -  -  6  
PP2-HA 6  10  5  5  1  2  6  300  
(0.5% 
w/v)  
300  
(0.5% 
w/v)  
2.4  
PP2-HA 30  10  5  5  1  2  30  300  
(0.5% 
w/v)  
300  
(0.5% 
w/v)  
2.4  
PP4-HA 30  20  10  10  1  4  30  300  
(0.5% 
w/v)  
300  
(0.5% 
w/v)  
2.4  
PP6-HA 30  30  15  15  1  6  30  300  
(0.5% 
w/v)  
300  
(0.5% 
w/v)  
2.4  
PP2-HA 60  10  5  5  1  2  60  300  
(0.5% 
w/v)  
300  
(0.5% 
w/v)  
2.4  
PP2-HA 30  
(no poloxamers 
water phase)  
10  5  5  1  2  30  -  -  3  
PP2-HA 30  
(1% poloxamers 
water phase)  
10  5  5  1  2  30  300  
(1% 
w/v)  
300  
(1% 
w/v)  
2.4  
Table 2.1: Formulations with different amount of HA, poloxamers, and PLGA 
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2.2.3 Nanoparticles characterization: morphology, mean size, size distribution and ζ 
potential 
 
Nanoparticles morphology was investigated through a transmission electron microscopy 
(TEM, FEI Tecnai G12 Spirit Twin) with emission source LaB6 (120 kV, spotsize 1) 
using 400 mesh carbon-coated copper grids at RT. The carbon-coated copper grid was 
immersed in ultradiluted NP suspension and, after the drying phase, the grid was placed 
on a rod holder for the TEM characterization. Three grids per NP suspension were 
prepared and a minimum of four micrographs per grid were acquired. 
Nanoparticles mean size, size distribution and ζ potential were determined by laser light 
scattering (LS, ZetaSizer Nano ZS, Malvern Instruments, Malvern, UK) on a ultra-
diluted suspensions in water (12 runs each sample). 
NP size, size distribution and ζ potential were also determined after 25 days  to assess 
device stability in the time. Stability tests were performed in order to verify a possible 
nanoparticles aggregation.  Results were averaged on at least five measurements.  
 
 
2.3 RESULTS AND DISCUSSION 
 
2.3.1 Morphological characterization 
 
The morphology of the nanoparticles was studied in distilled water at room temperature 
by transmission electron microscopy (TEM).  
Selected TEM micrographs of  nanoparticles at a PLGA concentration of 2% w/v 
indicated with P2 (figure 2.6), nanoparticles prepared with PLGA and poloxamers F68 
and F127 at a polymer concentration of 2% w/v indicated with PP2 (figure 2.7) and 
nanoparticles prepared with PLGA, poloxamers F68 and F127 at a polymer 
concentration in the organic phase of 2% w/v and different amount of HA (6 mg, 30 mg, 
60 mg) indicated with PP2HA6, PP2HA30, PP2HA60 (figure 2.8) were reported. 
From the figures it can be noticed that all the nanoparticles show a spherical shape.  
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Figure 2.6: Selected TEM micrographs of  nanoparticles of PLGA at a concentration 
of 2% 
 
In the case of nanoparticles of bare PLGA it is clear that an aggregation phenomenon 
occurred (figure 2.6). 
 
 
             Figure 2.7: Selected TEM micrographs of  nanoparticles of PLGA and 
poloxamers F68 and F127 at a polymer concentration of 2% 
 
By adding the poloxamers, nanoparticles relatively polydisperse and with a good 
dimensional stability were obtained (figure 2.7). 
 
 
P P 
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Figure 2.8: Selected TEM micrographs of  nanoparticles prepared with PLGA, 
poloxamers F68 and F127 at a polymer concentration of 2% and different amount of 
HA, 6 mg (A), 30 mg (B), 60 mg (C). 
 
TEM images of HA based NPs show that also in this case nanoparticles with a spherical 
shape were obtained but it can be noticed a sort of pockets, probably due to the 
interaction of HA with the polymers. Indeed, HA and poloxamers constitute a sort of 
tangled skein which coats the particle (figure 2.8). 
 
2.3.2 Mean size and size distribution  
The processing variables such as polymer concentration in organic phase, HA amount 
and poloxamers concentration influences the mean size and the size distribution. Hence 
the method was optimized to produce nanoparticles of small size and narrow size 
distribution.  
In table 2.2 the results in terms of size of bare PLGA NPs and NPs prepared with 
PLGA and poloxamers at different polymer concentrations (2 %, 4 %, 6 % w/v) were 
reported. The results demonstrate that the diameter of NPs slowly increases by 
increasing the PLGA concentration from 2 to 6 % w/v. Higher concentration of 
polymer produced a more viscous solution that caused a reduction in the rate of 
diffusion of polymer solution in the water phase. It is well accepted that the size of 
nanoparticles is directly dependent on the rate of diffusion of organic solvent to the 
outer aqueous environment. The faster the diffusion rate is, the smaller the particles 
would result [76-77]. 
Furthermore comparing the particles size of bare PLGA NPs and of NPs prepared with 
PLGA and poloxamers, it can be noticed that the size of bare PLGA NPs is bigger than 
A                        B                     C 
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the particles with PLGA and poloxamers. This result suggests that in the case of bare 
PLGA NPs there is an immediate aggregation and the presence of poloxamers 
influences positively  the stability of NPs. 
 
Formulation 
Particle mean 
diameter (0), [nm] 
Particle mean 
diameter (10 days), [nm] 
P 166.6 ± 0.4 260.4 ± 0.8 
PP 2% 110.2 ± 0.4 147.8 ± 0.4 
PP 4% 113.5 ± 1.8 147.8 ± 0.4 
PP 6% 129.8 ± 0.8 185.5 ± 1.3 
Table 2.2:  Results in terms of size and dimensional stability of bare PLGA NPs and 
NPs prepared with PLGA and poloxamers at different polymer concentrations (2 %, 4 
%, 6 % w/v) 
 
 
Formulation 
       Particle mean 
diameter (0), [nm] 
Particle mean 
diameter (10 days), [nm] 
PP2–HA30 290.5 ±11.9 287.9 ± 4.1 
PP4–HA30 301.0 ± 7.9 360.2 ± 7.8 
PP6–HA30 308.4 ± 14.9 332.1 ± 7.3 
Table 2.3:  Results in terms of size and dimensional stability of NPs prepared with 
PLGA, poloxamers and HA at different polymer concentrations (2 %, 4 %, 6 % w/v) 
and keeping constant HA amount (30 mg) 
 
In table 2.3 the effect of the adding of HA on NPs size was reported. In particular we 
show the dimensional results of NPs prepared with PLGA, poloxamers and HA at 
different polymer concentrations in the organic phase (2 %, 4 %, 6 % w/v)  keeping 
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constant HA amount (30 mg). The adding of HA in the formulations determined an 
increase of NPs size as it can be expected.  
In table 2.4 the effect of poloxamers concentration in the water phase on nanoparticles 
size, keeping constant PLGA and HA concentrations was shown. In particular the size 
of nanoparticles prepared with a polymer concentration in the organic phase of 2% w/v, 
an HA amount of 30 mg and different concentrations (0, 0.5% w/v, 1% w/v) of 
poloxamers (F68 and F127) solutions was reported. From the results it can be noticed 
that by varying the poloxamers concentration the better result in terms of NPs size was 
obtained in the case particles prepared with a poloxamer concentration of 0.5% w/v. 
 
 
Formulation 
F 68, w/v F 127, w/v 
Particle mean 
diameter (0), 
[nm] 
Particle mean 
diameter (25 
days), [nm] 
PP2–HA30 - - 330.2±20.6 369.7±21.4 
PP2–HA30 0.5% 0.5% 290.5±11.9 287.9±4.1 
PP2–HA30 1% 1% 349.2±36.5 312.6±27.8 
 
Table 2.4: Effect of poloxamers concentration on nanoparticles size and dimensional 
stability, keeping constant PLGA and HA concentration 
 
Furthermore the effect of HA amount on nanoparticles size, keeping constant PLGA 
and poloxamers concentrations was reported. In particular the diameter of particles 
prepared at PLGA and poloxamers concentrations in water phase of 2% w/v and 0.5% 
w/v respectively, and different amount of HA (6 mg, 30 mg, 60 mg) was shown in table 
2.5.  
The amount of HA is a crucial parameter in the design of the formulations because the 
quantitative of HA must be such that from a side a shell is formed around all the 
biodegradable core and on the other hand it must be not too big to lead to a phenomenon 
of NPs aggregation.  
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From the results it can be concluded that by varying the HA amount from 6 mg to 30 
mg and 60 mg the best formulation in terms of size is that of the NPs prepared at a HA 
amount of 6mg. By increasing the HA amount the nanoparticles size increases 
signifcatively and it is possible that an aggregation phenomenon was occurred. 
 
 
 
Formulation 
Particle mean 
diameter (0), [nm] 
Particle mean 
diameter (25 days), [nm] 
PP2–HA6 169.8 ±  4.2 186.1 ± 1.2 
PP2–HA30 290.5 ± 11.9 287.9 ± 4.1 
PP2–HA60 234.5 ±  4.1 231.4 ± 7.0 
Table 2.5: Effect of HA amount on nanoparticles size and dimensional stability, 
keeping constant PLGA and poloxamers concentrations 
This hypothesis is confirmed from the results related to the polydispersity index (PdI) 
reported in figure 2.9.  Infact by increasing the HA amount from 6 mg, to 30 mg up to 
60 mg, there is an increase of PdI from 0.3, that indicates a narrow size distribution, for  
PP2-HA 6, to 0.5  for  PP2-HA 30, to 0.7, that is indicative of a wide size distribution, 
in the case of PP2-HA 60.  
 
 
Figure 2.9: Polydispersity Index (PdI) of particles prepared at different HA 
amount (PP2-HA6, PP2-HA30, PP2-HA60) 
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2.3.3 Dimensional stability 
 
In the clinical administration of NPs, a phenomenon of particle aggregation may occur, 
affecting the drug release profile and probably implying vessel occlusion. For these 
reasons, the steric stability of nanoparticles is an important aspect to be considered.  
In table 2.2  the dimensional stability in the time of bare PLGA NPs and NPs prepared 
with PLGA and poloxamers at different polymer concentrations (2 %, 4 %, 6 % w/v) 
was reported. In particular the NPs diameter at time zero and after 10 days of NPs 
preparation was shown.  
Stability tests demonstrated that in the case of bare PLGA NPs there is an increase of 
NPs size of about 56 % in the time; so it can be concluded that after 10 days in the case 
of bare PLGA particles an aggregation phenomena occurred, while PLGA-Poloxamers 
particles size does not change significantly in the time. Therefore the presence of 
poloxamers influences positively dimensional stability of the particles. 
The dimensional stability of NPs prepared with PLGA, poloxamers and HA at 
different polymer concentrations (2 %, 4 %, 6 % w/v)  keeping constant HA amount 
(30 mg) was shown in table 2.3. The results demonstrated that the formulations 
prepared with HA show a good stability in the time in all cases. 
In table 2.4 the effect of poloxamers concentration in the water phase on dimensional 
stability of the nanoparticles, keeping constant PLGA and HA concentrations was 
shown. In particular the size of nanoparticles prepared with a polymer concentration in 
the organic phase of 2% w/v, an HA amount of 30 mg and different concentrations (0, 
0.5% w/v, 1% w/v) of poloxamers (F68 and F127) solutions was reported. From the 
results it can be noticed that by varying the poloxamers concentration the better result 
in terms of dimensional stability of the NPs was obtained in the case of particles 
prepared with a poloxamer concentration of 0.5% w/v. 
Furthermore the effect of HA amount on diamensional stability of the NPs, keeping 
constant PLGA and poloxamers concentrations was reported in table 2.5.  
In particular the diameter of particles prepared at polymer in organic phase and 
poloxamers in water phase concentrations of 2% w/v and 0.5% w/v respectively, and 
different amount of HA (6 mg, 30 mg, 60 mg) at time zero and after 25 days was 
shown.  
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From the results it can be concluded that all the formulations prepared at different 
amount of HA show a good dimensional stability in the time. 
In figure 2.10 the evaluation of the diameter in the time of the NPs prepared at a 
polymer concentration in the organic phase of 2% w/v, with an HA amount of 6mg and 
a poloxamers concentration of 0.5% w/v in water phase was reported. As it can be 
noticed the variation in the NPs size is not significative and the formulation prepared 
with HA show a very good stability probably due to the negative charge on the surface 
of the NPs that determines an electrostatic repulsion between the NPs. So this is the 
best formulation in terms of both size and dimensional stability. 
 
 
Figure 2.10: Dimensional stability in the time of nanoparticles PP2 HA 6 
 
2.3.4 Zeta potential 
In table 2.6  the results in terms of zeta potential of bare PLGA NPs and NPs prepared 
with PLGA and poloxamers at different polymer concentrations (2 %, 4 %, 6 % w/v) 
were reported. The zeta potential of bare PLGA NPs is around –27 mV; the presence 
of poloxamers and the variation of polymer concentrations does not effect on zeta 
potential.  
The zeta potential of NPs prepared with PLGA, poloxamers and HA at different 
polymer concentrations in the organic phase (2 %, 4 %, 6 %, w/v)  keeping constant 
HA amount (30 mg) was reported in table 2.7. The results show that the presence of 
HA in the formulations determines a decrease in the ζ potential; in particular the zeta 
potential passes from -27 mV in the case of particles without HA to -40 mV in the case 
of particles prepared with HA. The explanation of this phenomenon is related to the 
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negative charge of HA. This result can be an indication of the fact that HA was 
effectively settled around the biodegradable core of the particle forming a shell.  
 
 
 
Formulation 
Zeta potential (0),  
[mV] 
Zeta potential (10 days), 
 [mV] 
P -27.7 ± 2.0 -30.2 ± 2.1 
PP 2% -23.1 ± 2.3 -19.4 ± 2.2 
PP 4% -29.9 ± 0.6 -17.9 ± 3.5 
PP 6% -26.7 ± 1.9 -26.1 ± 0.7 
 
Table 2.6:  Results in terms of zeta potential of bare PLGA NPs and NPs prepared 
with PLGA and poloxamers at different polymer concentrations (2 %, 4 %, 6 % w/v) 
 
Formulation 
Zeta potential (0), 
 [mV] 
Zeta potential (10 days),  
[mV] 
PP2–HA30 -40.3 ± 2.9 -34.2 ± 8.1 
PP4–HA30 -37.6 ± 0.9 -31.9 ± 5.8 
PP6–HA30 -39.2 ± 3.1 -32.2 ± 2.5 
 
Table 2.7:  Results in terms of zeta potential of NPs prepared with PLGA, poloxamers 
and HA at different polymer concentrations (2 %, 4 %, 6 % w/v) and keeping constant 
HA amount (30 mg) 
 
In table 2.8 the effect of poloxamers concentration in water phase on nanoparticles zeta 
potential, was shown. In particular the zeta potential of nanoparticles prepared keeping 
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constant polymer concentration in the organic phase at 2% w/v, and HA amount at 30 
mg and at different concentrations (0, 0.5% w/v, 1% w/v) of poloxamers (F68 and 
F127) solutions was reported.  
From the results it can be noticed that even if the HA amount, that determines the 
negative charge of the NPs surface, is the same in all tested formulations, the NPs zeta 
potential changes from about -27 mV and -28 mV in the case of particles prepared at a 
poloxamers concentration of 0% and 1% w/v respectively to -40 mV in the case of 
particles prepared at a poloxamers concentration of 0.5% w/v.  
In the absence of poloxamers in the organic phase, particles show the same zeta 
potential of NPs prepared with bare PLGA, suggesting that probably without 
poloxamers in the organic phase, HA is not able to form a shell around the 
biodegradable core. When the poloxamers concentration is 0.5% w/v, the zeta potential 
decreases significantly probably due to the presence of HA around the particles. In the 
case of the result obtained by analyzing the zeta potential of NPs prepared with a 
poloxamers concentration of 1% w/v, it is possible that the poloxamers concentration 
is so high that a part of poloxamers takes place around HA shell, shielding the particle. 
From this results it can be concluded that in order to obtain nanoparticles characterized 
by a biodegradable core, a HA shell and poloxamers as bridge between hydrophobic 
core and hydrophilic shell, the optimum poloxamers concentration is 0.5% w/v. 
Formulation 
F 68,  
w/v 
F 127,  
w/v 
Zeta potential (0),  
[mV] 
Zeta potential (25 
days),  
[mV] 
PP2–HA30 - - -28.4±2.2 -27±3.1 
PP2–HA30 0.5% 0.5% -40.3±2.9 -34.2±8.1 
PP2–HA30 1% 1% -27.8±2.0 -35.1±3.4 
 
Table 2.8:  Effect of poloxamers concentration on nanoparticles zeta potential, 
keeping constant PLGA and HA concentration 
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Furthermore the effect of HA amount on nanoparticles zeta potential, keeping constant 
PLGA and poloxamers concentrations was reported. In particular the zeta potential of 
particles prepared with a polymer concentration in the organic phase of 2% w/v, 
poloxamers concentrations of 0.5% w/v in the water phase, and different amount of 
HA (6 mg, 30 mg, 60 mg) was shown in table 2.9.  
From the results it can be concluded that in the case of particles prepared with 6 mg 
and 30 mg of HA the zeta potential is about -40 mV; in the case instead of particles 
prepared with 60 mg of HA an increase of zeta potential from -40 mV to -22 mV was 
shown. A possible explanation of this phenomenon can be that in the case of particles 
at HA amount of 60 mg an aggregation between the nanoparticle occurred, resulting in 
a less exposed surface and therefore in an increase of the mean zeta potential. 
Formulation 
Zeta potential (0),  
[mV] 
Zeta potential (25 days), 
[mV] 
PP2–HA6 -37.3 ± 3.5 -29.4 ± 3.8 
PP2–HA30 -40.3 ± 2.9 -34.2 ± 8.1 
PP2–HA60 -22.2 ± 2.7 -24.6 ± 4.6 
 
Table 2.9:  Effect of HA amount on nanoparticles zeta potential, keeping constant 
PLGA and poloxamers concentrations 
 
2.3.5 Zeta potential stability 
 
Zeta potential stability tests in the time were performed on bare PLGA NPs and NPs 
prepared with PLGA and poloxamers at different polymer concentrations (2 %, 4 %, 6 
% w/v) (table 2.6).  In particular the NPs zeta potential at time zero and after 10 days 
of NPs preparation was shown. As it can be noticed from table 2.6 the zeta potential 
does not change in a significative manner in the time for all the formulations reported. 
The zeta potential stability of NPs prepared with PLGA, poloxamers and HA at 
different polymer concentrations in the organic phase (2 %, 4 %, 6 %, w/v), keeping 
constant HA amount (30 mg) was reported in table 2.7. The results demonstrate that 
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the presence of HA in the formulations determines a decrease in the ζ potential than 
the particles of bare PLGA and there is a good zeta potential stability in the time. 
Furthemore there is a slightly increase of zeta potential after 10 days from -40.3 ± 
2.9mV to -34.2 ± 8.1mV in the case of PP2 HA30, from -37.6± 0.9 mV to -31.9±5.8 
mV in the case of PP4 HA30 and from -39.2±3.1 mV to -32.2±2.5 mV in the case of 
PP6 HA30, probably due to the HA degradation in the time. 
In table 2.8  the effect of poloxamers concentration in the water phase on zeta potential 
stability was reported. In particular the zeta potential at time zero and after 25 days for 
the NPs prepared at the same polymer concentration (2% w/v) in the organic phase and 
the same amount of HA in the water phase (30 mg) and different F68 and F127 
concentration in the water phase (0, 0.5%, 1% w/v) was shown.  
As reported before without the presence of poloxamers in the external phase, the 
particles show the same potential of NPs of bare PLGA, indicating probably that HA 
was not binded to the biodegradable core.  
As regards particles prepared at a poloxamers concentration of 0.5% w/v the zeta 
potential passes from -40.3±2.9mV to -34.2±8.1 mV after 25 days. The zeta potential 
decreases because of the presence of HA and in the time probably increases for HA 
degradation. 
When poloxamers concentration is 1% w/v in the water phase the zeta potential passes 
from -27.8±2.0 mV to -35.1±3.4 mV after 25 days. In this case probably at time zero 
the poloxamers concentration is so high that poloxamers shield HA shell around the 
particle; in the time the interaction between HA shell and PEO segments of 
poloxamers can be weakened because of the stronger interaction between the 
hydrophilic groups of poloxamers and the water. 
The effect of HA amount on zeta potential stability of the nanoparticles was shown in 
table 2.9. In particular the zeta potential of particles prepared with a polymer 
concentration in the organic phase of 2% w/v, poloxamers concentrations of 0.5% w/v 
in water phase, and different amount of HA (6 mg, 30 mg, 60 mg) was reported.  
From the results it can be noticed that after 25 days all the formulations show an 
increase of zeta potential probably due to the HA degradation in the time. 
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2.4 CONCLUSIONS 
HA coated biodegradable NPs for tumor targeting were developed. The nanoparticles 
shown a spherical shape and a size ranging from 170 to 300 nm. In the case of bare 
PLGA particles immediate aggregation phenomena occured; HA addition allowed to 
obtain stable NPs size for more than 10 days. It’s important to underline that HA 
amount must be optimized to match possible tropism towards CD44 receptor and NP 
aggregation. 
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CHAPTER 3 
 
Irinotecan encapsulation and release from stable 
Hyaluronic Acid-Coated Biodegradable Nanoparticles 
 
ABSTRACT 
 
The preparation and characterization of a novel HA coated nanoparticulate system for 
tumor targeting were reported in the previous chapter. In this chapter the performance 
of these HA based nanoparticles (NPs) for the controlled release of a 
chemiotherapeutic drug, Irinotecan, mainly used for the colonrectal cancer therapy, 
Irinotecan, was evaluated. Thanks to the amphiphilic nature of these nanostructured 
systems characterized by a hydrophobic core and a hydrophilic shell, the NPs were 
able to successful encapsulate Irinotecan with a entrapment efficiency of 61.2 %. In 
vitro drug release was also evaluated. The results demonstrated that NPs were able to 
sustain a controlled release up to 24 days. 
 
 
3.1 INTRODUCTION 
 
The administration of drugs through the implantation or injection of drug delivery 
systems allows to obtain advantages over conventional drug therapies, facing limitations 
such as drug insolubility and instability in physiological environment and unspecific 
targeting [1-4]. 
In particular the entire quantity of drug necessary for a certain period is administered at 
once, and is released in a controlled manner, maintaining from a side drug concentration 
within therapeutic window and from another hand avoiding side effects [5-7].  
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In this context the design of advanced drug delivery systems and the development of 
carriers with properties suitable for the particular disease and treatment has become 
crucial [8-11]. 
In the previous chapter the preparation and the characterization of hyaluronic acid 
(HA)-coated nanoparticles were reported. In particular nanoparticles characterized by a 
biodegradable core of polylactic-coglycolic acid (PLGA), a shell of HA and anphiphilic 
polymers, known as Poloxamers or Pluronics, that act as a bridge between the 
hydrophobic PLGA and the hydrophilic HA were considered. 
Thanks to the presence of hydrophobic domains of PLGA, the particles can be stable 
sites for the encapsulation of poorly-water soluble drugs. On the other side HA is a 
natural and biocompatible material that does not trigger adverse reactions when it is 
injected in vivo [12-14]  and moreover it gives to the particle a hydrophilic character 
that allows long circulating times in body fluids [15-16]. 
Furthermore since HA can specifically bind to the cancer cells overexpressing at their 
surface CD44, an HA binding receptor [17-19], the particles can be efficiently 
internalized by the cells by means of both a passive (enhanced permeability and 
retention, EPR effect) and an active targeting [20-22]. 
Considering the afore mentioned features, these nanoparticles can be considered 
interesting systems as carriers of active agents.  
In order to assess their performance as drug carriers it is necessary to known the loaded 
amount of drug and its release kinetic from the particle. 
In particular in this chapter the encapsulation and the release of a chemoterapeutic 
agent, Irinotecan, was assessed.  
 
 
3.2 MATERIALS AND METHODS 
 
3.2.1 Materials  
 
Hyaluronic acid (HA) with a weight-average molecular weight (MW) of 850,000 Da 
was provided by Novozymes Biopharma (Denmark). Poly(lactic-co-glycolic acid) 
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(PLGA) (RG504H, MW 12,000 Da) was purchased from Boherniger Ingelheim 
(Germany).  
Poloxamers (PEOa-PPOb-PEOa), a group of amphiphilic triblock polymers, designed 
with variable numbers of oxyethylene (a) and oxypropylene (b) units, were employed. 
In particular in this study, poloxamer F127 (a=100 and b=65) and F68 (a=76 and 
b=29), obtained from Lutrol (Basf, Germany), were used. 
Irinotecan, acetone and dimethyl sulfoxide (DMSO) were obtained from Sigma 
Aldrich (USA). Sucrose were purchased from Riedel de Haen (Germany).  
Phosphate buffer saline (PBS) tablets without calcium and magnesium were obtained 
from MP Biomedicals Inc. (France). 
 
3.2.2 Drug-loaded Nanoparticles preparation  
 
Irinotecan loaded nanoparticles with and without HA were prepared by a single 
emulsion technique. In particular Irinotecan (2.5 mg) were added in the oil phase, 
prepared with 50 mg of PLGA, 25mg of F68, 25 mg of F127 and 5 ml of acetone. The 
water phase was characterized by 30 mg of HA dissolved in 12 ml of distilled water, 
1.5 ml of F68 solution (at 0.5% w/v) and 1.5 ml of F127 solution (at 0.5% w/v). The 
same formulation was prepared without HA in the water phase and without 
poloxamers in the organic phase. In particular Irinotecan (2.5 mg) was added in the oil 
phase, prepared with 100 mg of PLGA in 5 ml of acetone and emulsified with the 
water phase characterized by 12 ml of distilled water, 1.5 ml of F68 solution (at 0.5% 
w/v) and 1.5 ml of F127 solution (at 0.5% w/v). The formulation prepared with and 
without HA were indicated as PPH and P respectively. 
The organic phase was emulsified by vortexing for 5 min with the aqueous phase. The 
resulting emulsion was sonicated for 4 min at 4°C using a Branson Ultrasonic Cleaners 
(Model 3510) and the solvent was evaporated at room temperature for overnight.  
A solution of sucrose, prepared by mixing 600 mg of sucrose in 25 ml of bidistilled 
water,  was added to the NPs suspension. Nanoparticles were finally separated from 
supernatant by centrifugation at 13000 rpm for 60 minutes and lyophilized (Heto 
PowerDry PL6000 Freeze Dryer, Thermo Electron Corp., USA; -50 °C, 0.73 hPa) for 
24 h. 
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3.2.3 Mean size, dimensional stability and zeta potential 
 
Nanoparticles mean size and ζ potential were determined by laser light scattering (LS, 
ZetaSizer Nano ZS, Malvern Instruments, Malvern, UK) on a ultra-diluted suspensions 
in water (12 runs each sample). 
NP size were determined at time zero and after 25 days to assess devices stability in the 
time. Stability tests were performed in order to verify a possible nanoparticles 
aggregation.  Results were averaged on at least five measurements.  
 
 
3.2.4 Drug entrapment efficiency 
 
Drug entrapment efficiency was calculated by dissolving freeze-dried NPs (1 mg) in 1 
ml of DMSO. The resulting solution was sonicated (FALC, Italy) for 1 h in a water bath 
at 59 kHz, 100% power. 
Irinotecan content was quantified by measuring absorbance (UV-1800, UV-VIS 
spectrophotometer, Shimadzu, Japan) at 370 nm. The linearity of the spectrophotometer 
response was verified on Irinotecan solutions in DMSO (0.04–10 µg/ml concentration 
range; r2 > 0.99). Entrapped Irinotecan percentage was calculated as 
 ϐ ൌ ͳͲͲ כ   
 
Results were averaged on three batches. 
 
3.2.5 In vitro release kinetic of Irinotecan 
 
For release experiments, NPs were suspended in 10 ml of release medium (PBS at pH 
7.4) and incubated  at 37 °C in an orbital incubator (SI50, Stuart R, UK) operating at 
100 rpm. 
At scheduled time intervals, 1 ml aliquots were withdrawn and replaced with the same 
volume of fresh media. The aliquots were ultracentrifugated and the supernatant was 
analyzed through spectrophotometric analysis (λ = 364.5 nm) to assess the content of 
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Irinotecan. The instrument response was linear over the concentration range 0.1–50 
μg/ml (r
2 > 0.99). The experiments were run in triplicate. 
The release data were fitted to the following semiempirical equations, adapted from 
methods reported in literature and describing drug release from HA-based systems as 
the result of a Fickian diffusional and a degradation mechanisms [23]. 
 The diffusion contribution is expressed by: 
 ܨௗ௜௙௙ ൌ ܨௗ௜௙௙ǡ∞  ȉ ቀͳ െ ݁൫ି௞೏೔೑೑ȉ௧൯ቁ                                           (3.1) 
 
where  ܨௗ௜௙௙ǡ∞ is the burst fraction at time infinity and ݇ௗ௜௙௙ is the first order rate 
constant associated with the ‘burst’ release.  
The rate constant ݇ௗ௜௙௙ is equal to DACs/WLܨௗ௜௙௙ h1 where D and Cs are the diffusion 
coefficient and solubility of the drug, respectively, A is the surface area of drug 
available for dissolution and h1 is the apparent aqueous diffusion boundary layer 
thickness. Thus ݇ௗ௜௙௙  is expected to increase with increased drug solubility and surface 
area. 
The second release phase (ܨௗ௘௚), describing release of drug trapped in the polymer 
(1−ܨௗ௜௙௙ǡ∞) is considered dependent on polymer erosion and may be described by bulk 
degradation kinetics: 
 ܨௗ௘௚ ൌ ൫ͳ െ ܨௗ௜௙௙ǡ∞൯ ȉ ൫௘ሺೖ೟షೖ೟೘ೌೣሻ൯ሺଵା௘ሺೖ೟షೖ೟೘ೌೣሻሻ                               (3.2) 
 
where tmax and k are the time to the maximum rate and the rate constant respectively of 
the polymer degradation release phase. 
The overall released fraction is given by the sum of diffusional and degradation 
contributions, i.e.: 
 ܨ ൌ ܨௗ௜௙௙ ൅ ܨௗ௘௚ ൌ ܨௗ௜௙௙ǡ∞  ȉ ቀͳ െ ݁൫ି௞೏೔೑೑ȉ௧൯ቁ ൅ ൫ͳ െ ܨௗ௜௙௙ǡ∞൯ ȉ ൫௘ሺೖ೟షೖ೟೘ೌೣሻ൯ሺଵା௘ሺೖ೟షೖ೟೘ೌೣሻሻ      (3.3) 
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3.3 RESULTS and DISCUSSION 
 
3.3.1 Mean size and dimensional stability 
 
Size plays an important role in determining the drug release behavior of the irinotecan 
loaded nanoparticles.  It was demonstrated that particles with smaller dimension tends 
to accumulate in the tumor tissues due to the facilitated extravasation [24] and a better 
internalization occurs [25].  Furthermore smaller particles are easier to be intravenously 
injected and their sterilization may be simply done by filtration [26-27].  
In table 3.1 the results in terms of size of blank (PPH) and Irinotecan-loaded NPs 
(PPH+Irin) were reported. As it can be noticed the presence of drug implies an increase 
of NPs diameter from 169.8 ±  4.2 nm to 263 ± 3 nm. Although this result is 
unexpected, it can be explained considering that probably despite NPs were 
centrifugated in order to eliminate not-encapsulated drug, a small fraction of drug 
remains on the NPs surface promoting interactions between NPs. As confirmed by 
dimensional stability results, these interactions are sufficiently weak, infact after 25 
days the NPs size decreases from 263 ± 3 nm to  201 ± 1 nm. 
 
Formulation 
Particle mean 
diameter (0), [nm] 
Particle mean 
diameter (25 days), [nm] 
PPH 169.8 ±  4.2 186.1 ± 1.2 
PPH+Irin 263 ± 3 201 ± 1 
Table 3.1:  Size of blank (PPH) and Irinotecan-loaded NPs (PPH+Irin) measured at 
time zero and after 25 days. 
 
3.3.2 Zeta potential 
NPs surface charge is another important factor to be considered in the design of 
particles for drug delivery application. In table 3.2 the zeta potential of blank and 
Irinotecan-loaded NPs was reported. The results demonstrated that the presence of 
irinotecan does not affect the surface charge of NPs. 
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Formulation Zeta potential, [mV] 
PPH -37.3 ± 3.5 
PPH+Irin -35.78 ± 6 
Table 3.2: Zeta potential of blank (PPH) and Irinotecan-loaded NPs (PPH+Irin)  
 
3.3.3 Drug entrapment efficiency 
 
The results related to the drug encapsulation efficiency are summarized in table 3.3. The 
drug content was found to be 58.8 % (w/w) in the case of particle prepared with bare 
PLGA and 61.2 % (w/w) in the case of particle prepared with a polymer concentration 
in the organic phase of 2% (w/v), a poloxamers concentration in the water phase of 
0.5% (w/v)  and HA amount of 30 mg. 
 
Formulation Encapsulation efficiency 
EE % 
P 58.8 
PPH 61.2 
 
Table 3.3: Percentage of drug encapsulation efficiency of particle prepared with 
bare PLGA (P) and with the adding of poloxamers and HA in the formulation 
(PPH). 
 
The results demonstrated that the presence of HA does not affect significantly the drug 
entrapment efficiency. 
 
3.3.4 In vitro release kinetic of Irinotecan 
Experimental and simulated in vitro fractional release profiles of Irinotecan from 
nanoparticles P and PPH in phosphate buffer were reported in figures 3.1 and 3.1.  
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The results demonstrated that nanoparticles P and PPH were able to sustain the 
Irinotecan release for at least 24 days. From figures 3.1 and 3.2 it can be noticed that 
after 24 h a burst effect occurred. In particular after 24 h a released Irinotecan fractions 
were 0.336 and 0.261 from nanoparticles P and PPH respectively. Furthermore the 
experimental data were fitted by a mathematical model reported in the methods section. 
The applied model allowed to discriminate the degradation and diffusion contributions 
to Irinotecan release from NPs. In table 3.4 the models parameters obtained by fitting 
experimental release data to equation 3.3 were reported.  
The results shown that the Irinotecan release from NPs is due to the combination of 
diffusional and degradation mechanisms. The release profiles shown that the initial 
release is controlled by diffusion; the degradation mechanism, instead governs a 
secondary slower release. 
 
 NPs P NPs PPH ܨௗ௜௙௙ǡ
∞
 0.150± 0.009 0.127± 0.02 ݇ௗ௜௙௙, h-1 0.063± 0.001 0.040± 0.0005 ݇, h-1 0.007± 0.0002 0.008± 0.0004 ݐ௠௔௫ ǡ   166.5± 10 191.5± 13 
Table 3.4: Model parameters as calculated by fitting experimental release data to Eq. 
3.3. 
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Figure 3.1: In vitro Irinotecan release profiles from nanoparticles P. Solid lines 
represent model simulations. Fitting was performed by Eq. 3.3 
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Figure 3.2: In vitro Irinotecan release from nanoparticles PPH. Solid lines represent 
model simulations. Fitting was performed by Eq. 3.3 
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3.4 CONCLUSIONS 
 
In this chapter the drug encapsulation efficiency and in vitro drug release for a novel 
nanoparticulate system, using Irinotecan as drug model, were evaluated. The 
amphiphilic nature of these nanostructured devices, characterized by a inner 
hydrophobic core and a hydrophilic shell, allowed to obtain a drug encapsulation 
efficiency of 61.2% and in vitro sustained Irinotecan release up to 24 days. 
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CHAPTER 4 
 
Preparation And Characterization Of Novel Self-Associative 
Nanostructured Soft Carriers Based On Amphiphilic 
Hyaluronic Acid Derivatives 
 
ABSTRACT 
 
The idea of this study was to combine Hyaluronic acid (HA) viscosupplementation and 
a local/controlled delivery of a hydrophobic anti-inflammatory drug. 
In particular the ability of an octenyl succinic anhydride (OSA) modified HA (OSA-
HA), to act as a viscosupplementation agent and as a drug delivery system wanted to be  
investigated. 
To do this a characterization of these systems was necessary. For this reason  
morphological, dimensional, calorimetric and rheological studies of this novel HA 
derivatives were conducted. From morphological analysis it resulted that micelles are 
spherical objects with diameters around 100 nm. Differential scanning calorimetric 
(DSC) analysis revealed that the ability of HA to sequester water seems to be enhanced 
by the introduction of lipophilic functions within HA molecules, resulting in a further 
decrease of the fraction of free water able to freeze compared to the unmodified HA. 
Moreover, OSA-HA solutions appeared to be an appropriate tool to be used in 
viscosupplentation therapy owing to their suitable viscoelastic features.  
 
4.1 INTRODUCTION 
 
Amphiphilic copolymers, once in an aqueous solutions, can self-assemble into micelles 
owing to a high solubility difference between the hydrophilic and the hydrophobic 
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segments [1, 2, 3].These systems can be used as drug delivery carriers due to their 
potential high drug-loading capacity and possibility to load a variety of drugs with 
diverse features into the hydrophobic core of the micelles to treat several diseases [4, 5].  
Hyaluronic acid (HA) is a natural mucoadhesive polysaccharide, a main constituent of 
the extracellular matrix of connective tissues, which displays biodegradability and 
biocompatibility properties. It is composed of alternating D-glucuronic acid (GlcA) and 
N-acetyl-D-glucosamine (GlcNAc) repeating units linked together via β-(1,4) and β-
(1,3) glycosidic junctions [6]. HA is a major ligand of the adhesion receptor CD44, 
which is also expressed at the surface of chondrocytes [7]. In solution, HA displays an 
extraordinary capability to retain water, and behaves as an expanded random coil 
occupying a large hydrodynamic volume. This causes neighboring molecules to overlap, 
thus forming the transient network structure with a marked viscoelasticity [8]. These 
compelling features make HA a ductile and versatile biopolymer used for several 
applications in the biomedical field. For instance, HA is commonly used in topical 
ophthalmology for the dry eye treatment and as a viscoelastic device in ophthalmologic 
surgery owing to the ability to form highly viscous solutions even at low concentrations 
[9, 10, 11, 12]. Moreover, intra-articular injection of HA (viscosupplementation) is one 
of the most used therapies for the treatment of knee osteoarthritis, its goal being to 
restore the elastic and viscous properties of the synovial fluid (SF) [13, 14]. Pathologic 
alterations occurring in joint diseases, indeed, lead to a decrease in SF of HA molecular 
weight and concentration, and consequently a decline in SF viscoelastic properties [15]. 
The beneficial improvements in SF viscoelastic properties, and joint functions, derive 
from both the intrinsic viscoelastic properties of HA and its potential stimulatory effect 
on the synthesis of high molecular weight HA by synoviocytes [16]. Currently, several 
viscosupplemention products based on HA are commercially available and an important 
research effort has been devoted to chemically modify HA, through coupling or 
crosslinking reactions, preserving its biocompatibility. Indeed, native HA, once in vivo, 
undergoes a rapid degradation due to its sensitivity to hyaluronidase and high 
hydrophilicity. To avoid these drawbacks, among the possible chemical modification, 
various pendant chains have been grafted onto HA to increase its residence time and 
viscoelastic features [14]. Many chemical modifications involving HA carboxyl and/or 
hydroxyl groups to obtain a proper HA molecule for different applications were 
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investigated [17]. In particular as regards to the modification of HA carboxyl groups, an 
alkylated derivatives of HA was obtained using alkyl aldehydes in water/ethanol 
mixtures in the presence of sodium cyanoborohydride [18]. Furthermore alkyl bromides 
in dimethyl sulfoxide (DMSO) was used for the preparation of an amphiphilic water 
soluble derivatives of HA [19]. Methyl ester HA derivatives was also obtained using 
alkyl silyl diazomethanes in methanol/diethyl ether mixtures [20].   
Other more recent modifications of HA molecule involve hydroxyl groups; in particular  
HA hydroxyl groups were modified with acylchlorides in N, N dimethylformamide 
(DMF) in the presence of pyridine [21] or with alkyloxymethyloxiranes in a 
water/DMSO mixture [22] or also with aryl-or alkyl-vinyl sulfones in water/acetone 
mixtures in the presence of sodium hydroxide [23] (table 4.1).  
 
 
HA group 
involved 
Group used to modified 
HA 
Solvent Reference 
-COOH 
alkyl aldehydes water/ethanol mixtures [18] 
alkyl bromides DMSO [19] 
alkyl silyl diazomethanes 
methanol/diethyl ether 
mixtures 
[20] 
-OH 
acylchlorides N, N dimethylformamide [21] 
alkyloxymethyloxiranes water/DMSO mixture [22] 
aryl-or alkyl-vinyl sulfones water/acetone mixtures [23] 
Table 4.1: HA modifications involving carboxyl and hydroxyl groups 
 
 
However the current methods used to modify the HA molecule are characterized by 
some drawbacks. First the modifications involving HA carboxyl groups could modify 
the distribution of negative charges along the molecule, affecting important biological 
and pharmacological properties of native HA [24]. Secondly organic solvents or organic 
solvent/water mixtures were used in the reactions and this implies environmental issues, 
limits the upscalability of the preparation methods and often requires converting HA 
into its tetraalkylammonium salt or preparing reactive HA intermediates that makes 
more complex the preparation methods and often results in HA degradation. 
Moreover, to stimulate the production of healthy HA and facilitate the homeostasis in 
the joint region, oral administration of anti-inflammatory drugs is often necessary in 
combination, or as an alternative to HA viscosupplementation. However, the prolonged 
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use of such drugs can cause important systemic adverse effects and, therefore, intra-
articular injections of anti-inflammatory drug/s are often practiced [25]. However, 
conventional dosage forms do not provide a prolonged release of the drug, thus leading 
to the necessity of frequent injections, which can cause inflammations and lower patient 
compliance. To avoid these drawbacks, a local/sustained delivery of anti-inflammatory 
drug would be desirable. 
In this frame, the idea of this study was to design and characterize a delivery system 
and, at the same time, able to restore the viscoelastic features of pathologic SF.  
To this aim, an amphiphilic HA derivative able to selfassemble into micelles and 
possessing suitable viscoelastic features to act as a viscosupplementation agent was 
designed. 
A new amphiphilic HA derivative and, in particular, an octenyl succinic anhydride 
(OSA) modified HA was synthesized through a simple reaction in an aqueous medium, 
which involves exclusively HA hydroxyl groups [26]. The resulting derivatives present 
great potential since, first of all, no organic solvents are used in the reaction, thus 
avoiding environmental issues and allowing the upscalability of the preparation method; 
secondly, the reaction does not involve HA carboxyl groups which can neutralize 
negative charges along the polymer backbone. Actually, it is important to maintain the 
charge distribution that can confer an electrostatically-induced stability in the 
perspective of using the self-assembling properties of these derivatives towards the 
design of micelles for the delivery of poorly soluble drugs. 
In this chapter preliminary studies based on a morphological, dimensional, calorimetric 
and rheological characterization of this novel HA derivatives were conducted.  
 
4.2 MATERIALS AND METHODS 
4.2.1 Materials 
Hyaluronic acid (HA) with a weight-average molecular weight (MWw) of 850,000 Da 
(HA850) was provided by Novozymes Biopharma (Denmark). Octenyl succinic 
anhydride (OSA; MW: 210.27 Da, purity P97%, mixture of cis and trans) salts was 
obtained from Sigma-Aldrich (USA). Distilled water from Milli-Q (Millipore, USA) 
was used. OSA-HA derivatives, with a percentage of substitution of 6%, were provided 
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by Novozymes. They were synthetized as previously reported [26], and briefly 
summarized in the following Methods section. 
4.2.2 Preparation of hyaluronic acid derivative 
 
OSA-modified derivative at 6% degree of substitution was prepared by dissolving 
HA850 overnight at room temperature in de-ionized water. NaHCO3 was added to the 
solution and mixed at room temperature (RT) for 1h. Afterwards, the pH of the HA 
solution was adjusted to 8.5 with NaOH (0.5 M). OSA was added dropwise to the 
alkaline HA solution under vigorous stirring. The reaction medium was mixed at RT 
and the resulting crude product was dialysed against milli-Q water (7.5 L) using 
molecular porous membrane tubing (Spectra/Por®4, MWCO 12,000–14,000 Da; 
Spectrum Laboratories, Rancho Dominguez, California, United States) at 4 °C. The 
purified OSA–HA was finally freeze-dried. OSA-HA solutions were prepared by 
dissolving OSA-HA powder in bidistilled water or phosphate buffer saline (PBS; 120 
mM NaCl, 2.7 mM KCl, 10 mM phosphate salts; pH 7.4) in the 0.1÷5% w/v 
concentration range. 
4.2.3 Differential Scanning Calorimetry (DSC) 
 
Thermoanalytical tests were carried out on solutions of HA and OSA-HA to study how 
the chemical modification could influence the interactions between the polysaccharide 
chains and water. The heat involved in the solid-to-liquid phase transition of water 
within HA solutions was determined by a differential scanning calorimeter (DSC; DSC 
Q20, TA Instruments, U.S.A.), calibrated with a pure indium standard. The samples 
were prepared in flasks by simple stirring overnight at room temperature, until 
transparent and homogeneous solutions were obtained. The samples were placed in 
hermetically sealed aluminum pans, equilibrated at –30°C and heated to 20°C at 
2°C/min. Measurements were carried out under an inert nitrogen atmosphere, purged at 
a flow rate of 50.0 mL/min. The heat evolved by the fusion of water (W/g) within the 
solutions was calculated from the recorded DSC thermograms by integrating the 
endothermic melting peaks and normalized with respect to the actual content of water. 
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4.2.4 Morphology and size distribution of OSA-HA micelles 
 
The morphology of OSA-HA micelles were investigated by transmission electron 
microscopy (TEM, FEI Tecnai G12 Spirit Twin) with emission source LaB6 (120 kV, 
spotsize 1) using 400 mesh carbon-coated copper grids at RT. The OSA-HA solutions at 
1 mg/ml, in water and PBS, were prepared. The carbon-coated copper grid was 
immersed in OSA-HA solution and, after the drying phase, the grid was placed on a rod 
holder for the TEM characterization. Three grids per OSA-HA solution were prepared 
and a minimum of four micrographs per grid were acquired.  
Micelle mean size and size distribution were determined by laser light scattering (LS, 
ZetaSizer Nano ZS, Malvern Instruments, Malvern, UK) on a ultra-diluted suspensions 
in water (12 runs each sample). 
 
4.2.5 Rheological properties 
 
Small amplitude oscillatory shear tests were performed to evaluate the time-dependent 
response of these materials and their linear viscoelastic properties (G’, G’’). The 
frequency was in the range from 0.01 to 10 Hz. The measurements were carried out 
through a strain controlled rotational rheometer (Gemini Bohlin Instruments, UK), using 
a parallel plate geometry (PP30 cell). The tests were carried out at the controlled 
temperatures of 25 and 37°C using a thermostatic bath. 
In a dynamic test the material is subjected to a sinusoidal shear strain: 
 ߛ ൌ ߛ଴ ሺ߱ݐሻ                     (4.1) 
 
where ߛ଴ is the shear strain amplitude, ω is the oscillation frequency (which can be also 
expressed as 2 f, where f is the frequency in Hz) and t the time. The mechanical 
response, expressed as shear stress τ of viscoelastic materials, is intermediate between 
an ideal pure elastic solid (obeying to the Hooke's law) and an ideal pure viscous fluid 
(obeying to the Newton's law) and, therefore, it is out of phase with respect to the 
imposed deformation as expressed by: 
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߬ ൌ ܩᇱሺ߱ሻ ȉ ߛ଴ ሺ߱ݐሻ ൅ ܩᇱᇱሺ߱ሻ ȉ ߛ଴ ሺ߱ݐሻ                  (4.2) 
 
where ܩᇱሺ߱ሻ is the storage or elastic modulus and ܩᇱᇱሺ߱ሻ is the loss or viscous 
modulus. G' gives information about the elasticity or the energy stored in the material 
during deformation, whereas G" describes the viscous component or the energy 
dissipated as heat. Since viscoelastic properties strongly depend upon the time-scale of 
observation, it will be reported the dependence of G' and G" upon the frequency, the so 
called mechanical spectrum. 
In order to identify the linear viscoelastic response range of the materials, preliminary 
strain sweep tests were performed on the samples, at the oscillation frequency of 1 Hz. 
The tests were repeated at least three times on each sample. 
 
4.3 RESULTS and DISCUSSION 
 
An amphiphilic HA derivative based on the reaction between HA and OSA in mildly 
alkaline aqueous media was previously developed through a novel and easily upscalable 
modification method [26] (figure 4.1). The obtained polymer can be regarded as a 
fishbone-like macromolecule consisting of a linear backbone carrying randomly 
distributed hydrophobic octenyl succinate (OS) side groups with a 6% degree of 
substitution (DS). 
 
Figure 4.1: Scheme of chemical modification of HA with OSA. 
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4.3.1 Differential Scanning Calorimetry (DSC) 
 
Figure 4.2 shows DSC thermograms of water, HA and OSA-HA (DS = 6 %) solutions. 
As shown in the figure, in all cases a single melting peak, caused by the fusion of free 
water was observed. Melting temperature (Tm) was here defined as the temperature at 
which the DSC curve shifts towards the endothermic direction. In particular, Tm 
obtained with HA and OSA-HA solutions were found to be lower than that of pure 
water. The heat of fusion was 335.9, 320.2 and 302.8 J/g for water, HA and OSA-HA, 
respectively, as reported in Table 4.2. 
 
 
mHD , (J/g) mT , (°C) 
Water 335.9 ± 2.7 0.21 ± 0.28 
HA (DS = 0) 320.2 ± 5.9 -5.88 ± 1.07 
OSA-HA (DS = 6%) 302.8 ± 9.2 -7.39 ± 1.05 
Table 4.2: Melting enthalpies and temperatures of water, HA and OSA-HA 
 
The decrease of Tm in the case of HA and OSA-HA solutions was associated to the 
occurrence of intermolecular interactions between HA and water. Likewise, the 
reduction of peak areas in the presence of HA, and hence of the melting enthalpies, 
could also be ascribed to the interactions of HA chains with water. It is well known that 
a certain number of water molecules are restrained in the junction zone where the 
polysaccharide chains interact among each other to form a gel network structure, thus 
reducing the amount of free water available for freezing [27]. In our case, both Tm and 
melting enthalpy of OSA-HA were found to be lower compared to unsubstituted HA. 
This result can indicate that the ability of HA to sequester water seems to be enhanced 
due the introduction of lipophilic functions within HA molecules, thus resulting in a 
further decrease of the fraction of free water able to freeze compared to the unmodified 
HA. 
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Figure 4.2: Representative endotherms for pure water, unsubstituted HA, OSA-HA (DS 
= 4.6%). Exotherm is oriented upwards. 
 
4.3.2 Morphology and size distribution of OSA-HA micelles 
 
In figures 4.3A and 4.3B selected TEM images of OSA-HA micelles at 1 mg/ml, in 
water and PBS respectively, are shown. As it can be seen, micelles are spherical objects 
with diameters around 100 nm in both water and PBS. Figure 4.4 presents LS 
measurements of OSA-HA micelles. This analysis evidenced the presence of a 
somewhat polydisperse population of objects with a mean diameter of about 400 nm. 
The discrepancy between the results of these techniques could be due to micelle 
aggregation. It is, indeed, likely to occur a dispersion of spherical hydrophobic domains, 
formed by the pendant OS groups, surrounded by a hydrophilic matrix of unmodified 
HA chains that interact each other through intra- and intermolecular hydrogen bonds. 
This hypothesis of micelle aggregation is also suggested by the difference in the 
molecular weight of HA chains and OS side groups. As a consequence, through TEM 
analysis it is possible to directly obtain a single micelle picture which appears spherical 
with a diameter in the order of 100 nm. In a LS experiments, instead, the Brownian 
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motion of micelles in suspension causes the scattering of a laser light at different 
intensities which are correlated to particle size trough the Stokes-Einstein relationship. 
In this latter case, the laser light can be scattered by a single micelle or by a group of 
aggregated micelles, as previously described, thus giving higher apparent mean 
diameter values of the micelles. A schematic representation of the possible organization 
of the OSA-HA micellar system is depicted in figure 4.5. Analogous results were 
obtained for the low molecular weight OSA-HA derivative, as previously reported [28]. 
 
 
Figure 4.3: Selected TEM images of OSA-HA micelles at 1 mg/ml in water (A) and 
PBS (B). 
 
 
 
 
Figure 4.4: PCS results of OSA-HA micelles  
 
A B
C
C
D
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Figure 4.5: Graphical representation of the hypnotized structure of OSA-HA 
micelles 
 
4.3.3 Rheological properties 
 
In the perspective of using the novel OSA derivatives as viscosupplementation products, 
the rheological features assume a crucial role since they must properly restore the 
biomechanical functions of the normal SF. To this aim, the rheological properties of 
unmodified and modified HA solutions were studied to evaluate the effect of the 
chemical modification, concentration and ionic strength of the dissolving medium.  
In figure 4.6 the elastic and the viscous moduli curves as a function of the oscillation 
frequency (mechanical spectra) of HA and OSA-HA solutions at 50 mg/ml in PBS and 
distilled water are reported. Both HA and OSA-HA solutions behave as entangled 
solutions; indeed they are namely viscous at low frequency (G’’ > G’) and prevalently 
elastic at high frequencies (G’ > G’’); the limit between the two regions is represented 
by the crossover frequency. These observations can be explained by consideration of the 
following. At low frequencies, the molecular chains can release stress by 
disentanglement and molecular rearrangement during the period of oscillation, and 
hence, the solution shows viscous behavior (G’’ > G’). At high frequencies, however, 
molecular chains cannot disentangle during this short period of oscillation, and 
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therefore, they behave as a temporarily cross-linked network, and the elastic behavior 
(G’ > G’’) is prevalent. Furthermore, from a quantitative point of view, both the 
viscoelastic parameters of OSA-HA solutions are lower than the corresponding values 
of the unmodified HA solutions. In particular, at 1 Hz, G’ ad G’’ values, at 50 mg/ml in 
water, decreases from 369 to 111 Pa and from 417 to 181 Pa respectively, and the cross 
over frequency increases from ~ 1 Hz to ~ 4 Hz.  
 
Figure 4.6: Mechanical spectra of HA and OSA-HA solutions at 50mg/ml in water and 
PBS. 
 
This result can be explained taking into account that the chemical modification leads to 
a shrinkage of the macromolecular coils which, in turn, reduce the probability of 
intermolecular interactions with a consequent weakening of the polymeric network 
which become prevalently elastic at higher frequency. Moreover, these results 
highlighted that ionic strength does not affect the rheological properties of HA and 
OSA/HA solutions. Indeed, the mechanical spectra in PBS and water were found to be 
identical. 
Figures 4.7 A, B, C report the mechanical spectra of OSA-HA solutions at 10 mg/ml, 25 
mg/ml and 50 mg/ml and in Table 4.3 the viscoelastic parameters of OSA-HA solutions 
at f = 2Hz are shown. It can be noticed that the increase of OSA-HA concentration leads 
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to an increase of both the elastic and the viscous moduli. In particular, the values of both 
viscoelastic parameters increase of one order of magnitude passing by 10 mg/ml to 25 
mg/ml and of two orders of magnitude passing by 25 mg/ml to 50 mg/ml. This result 
can indicate that the increase of OSA-HA concentration leads to an enhanced 
organization. The OSA-HA solutions exhibit a rheological behavior similar to the 
human synovial fluid, that is viscous at low frequencies and prevalently elastic at high 
frequencies and characterized by the presence of crossover frequency [29]. 
Furthermore the our amphiphilic HA derivatives show higher values of both viscous and 
elastic moduli than those of healthy human synovial fluid; in particular in the case of the 
OSA-HA solutions at a concentration of 50 mg/ml, G’ and G’’ reach the values of 249 
and 234 Pa, respectively. 
The rheological features of OSA-HA solutions are particularly attractive for 
viscosupplementation applications aimed at restoration of the viscoelasticity of diseased 
SF. Several products are currently used in viscosupplementation which differ in HA 
source, molecular weight, concentration and chemical modification thus resulting in a 
wide array of rheological behaviors from both qualitative and quantitative standpoints.  
For example, at a frequency of 2 Hz, HYALGAN® is characterized by G’ and G’’ of 
respectively 0.1 and 0.8 Pa, HYADD4, a derivative of HA, presents an elastic modulus 
of 40 Pa and a viscous modulus of 10 Pa, and SYNVISC HYLAN G-F20®, made of 
cross-linked HA, shows the elastic and viscous moduli values of about 98 Pa and 20 Pa 
respectively, [30-31, 13]. It can be noticed that OSA-HA solutions, at a concentration of 
50 mg/ml, show values of G’ higher than those of viscosupplementation products 
currently used in clinical practice. The prevalent elastic character of an HA-based 
viscosupplementation products is not a problem being desirable in osteoarthritis 
applications. This is not only because of its capability to reduce the mechanical energy 
applied on the cartilage, but also because HA derivatives, with high elasticity, show 
analgesic ability. It has been reported that substances with enhanced elastic 
characteristics reduce the effect of nociceptive stimulus on medial articular nerve 
activity and decrease the sensory response to passive movements of inflamed knee 
joints. Hypothetically, this positive effect is due to their capacity to absorb a significant 
part of the mechanical energy of the stimulus, thus reducing the transmission to the 
mechano-transduction apparatus where pain signal originates. 
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Figure 4.7: Mechanical spectra of OSA-HA solutions at 10 mg/ml (A), 25 mg/ml (B) 
and 50 mg/ml (C). 
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[HAosa], (mg/ml) G’, (Pa) G’’, (Pa) 
10 0.72 2.14 
25 1.34 6.57 
50 249 234 
Table 4.3: Viscoelastic parameters of OSA-HA solutions at f = 2 Hz 
 
4.4 Conclusions 
 
In this study the morphological, calorimetric and rheological study of a novel 
amphiphilic high molecular weight HA derivative and, in particular, an octenyl succinic 
anhydride (OSA) modified HA (OSA-HA) was reported.  
From morphological analysis it resulted that micelles are spherical objects with 
diameters around 100 nm.  
Differential scanning calorimetric (DSC) analysis revealed that the ability of HA to 
sequester water seems to be enhanced by the introduction of lipophilic functions within 
HA molecules, resulting in a further decrease of the fraction of free water able to freeze 
compared to the unmodified HA. 
Finally, OSA-HA, thanks to its suitable viscoelastic features, is potentially useful in 
restoring SF rheological properties during a viscosupplementation therapy. 
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CHAPTER 5 
 
Hydrophobic Drug Release From Micelles Based On 
Amphiphilic Hyaluronic Acid Derivatives  
 
ABSTRACT 
 
In the previous chapter the preparation and morphological, dimensional, calorimetric 
and rheological characterization of novel self associative nanostructured soft carriers 
based on an amphiphilic hyaluronic acid derivative were reported and it was 
demonstrated that these systems appeared interesting tools to be used in 
viscosupplentation therapy owing to their suitable viscoelastic features. In this chapter  
the ability of these systems to self-assemble into micelles, load a hydrophobic drug,  
release the active molecule in situ with controlled kinetics and to act as a solubility 
enhancer was studied. 
 
5.1 INTRODUCTION 
 
Hyaluronic acid (HA) is a naturally occurring polysaccharide, mainly present in the  
extracellular matrix of connective tissues [1]. 
It is composed of alternating D-glucuronic acid and N-acetyl-D-glucosamine repeating 
units linked together via β-(1,4) and β-(1,3) glycosidic junctions [2-6].  
Thanks to its versatile properties, such as biocompatibility, nonimmunogenicity, 
biodegradability and viscoelasticity, it has been used for several biomedical 
applications. With the development of different strategies for the modification of its 
structure, HA has become an important building blocks for the production of new 
biomaterials to be used in regenerative medicine and drug delivery [7-10]. 
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Although HA is an excellent biomaterial, because of its hydrophilic nature, native 
HA is unsuitable for the encapsulation of hydrophobic drugs. 
In order to overcame this problem, the strategy used was to modify HA molecules 
with hydrophobic groups, obtaining a more favourable starting material for the 
production of stable nanostructures and the durable encapsulation of hydrophobic 
drugs. 
However the current methods used for the preparation of amphiphilic HA present 
some drawbacks. The first one is the use of organic solvent in the modification 
reaction that implies environmental issues, limits the upscalability of the preparation 
methods and moreover often requires converting HA into its tetraalkylammonium salt 
or preparing reactive HA intermediates that makes more complex the preparation 
methods and often results in HA degradation [11]. 
On the other hand the HA modifications involve carboxyl groups resulting in an 
alteration of the distribution of negative charges along the polymer backbone at 
physiological pH and probably affecting fundamental biological and pharmacological 
HA properties. 
Therefore the aim of this work was to design a delivery system based on an 
amphiphilic HA derivative able to self-assemble into micelles, load a hydrophobic 
drug and release the active molecule in situ with controlled kinetics. The new 
syntetized amphiphilic HA derivative is an octenyl succinic anhydride (OSA) 
modified HA, obtained through a simple reaction in an aqueous medium, and which 
involves exclusively HA hydroxyl groups [12]. 
Theses derivatives present great potential since, firstly no organic solvents are used in 
the reaction, thus avoiding environmental issues and allowing the upscalability of the 
preparation method; secondly, the reaction does not involve HA carboxyl groups 
which can neutralize negative charges along the polymer backbone. Actually, it is 
important to maintain the charge distribution that can confer an electrostatically-
induced stability in the perspective of using the self-assembling properties of these 
derivatives toward the design of micelles for the drug delivery of poorly soluble drugs. 
In particular the idea of this work was to study to the release of a commonly used 
hydrophobic anti-inflammatory drug to treat joint pathologies, known as triamcinolone 
acetonide (TA). 
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In the treatment of osteoarthrite, in order to stimulate the production of healthy HA 
and facilitate the homeostasis in the joint region, oral administration of anti-
inflammatory drugs is often necessary in combination, or as an alternative to HA 
viscosupplementation [13-17]. However, the prolonged use of such drugs can cause 
important systemic adverse effects and, therefore, intra-articular injections of anti-
inflammatory drug/s are often practiced [18]. However, conventional dosage forms do 
not provide a prolonged release of the drug, thus leading to the necessity of frequent 
injections, which can cause inflammations and lower patient compliance. To avoid 
these drawbacks, a local/sustained delivery of anti-inflammatory drug would be 
desirable. 
For these reasons the idea was to design a delivery system able to prolong the release 
of an anti-inflammatory drug into the joint cavity and, at the same time, able to restore 
the viscoelastic features of pathologic synovial fluid, acting as a viscosupplementation 
agent. 
In the previous chapter morphological, dimensional, calorimetric and rheological 
studies of these systems were reported and it was demonstrated that OSA-HA 
solutions appeared to be an appropriate tool to be used in viscosupplentation therapy 
owing to their suitable viscoelastic features.  
In this chapter the ability of this novel amphiphilic HA derivative to selfassemble into 
micelles and to act as a solubility enhancer and as a modulator of release kinetics of 
TA was investigated. 
5.2 MATERIALS AND METHODS 
5.2.1 Materials 
Hyaluronic acid (HA) with a weight-average molecular weight (MWw) of 850,000 Da 
(HA850) was provided by Novozymes Biopharma (Denmark). Octenyl succinic 
anhydride (OSA; MW: 210.27 Da, purity P97%, mixture of cis and trans) salts and 
HPLC-grade solvents were obtained from Sigma-Aldrich (USA). Distilled water from 
Milli-Q (Millipore, USA) was used, and triamcinolone acenotide (TA) was obtained 
from Farmalabor (Italy). OSA-HA derivatives, with a percentage of substitution of 
6%, were provided by Novozymes. They were synthetized as reported in the previous 
chapter. 
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5.2.2 Preparation of solutions 
 
The solutions for the dissolution tests and drug release kinetics were prepared by 
adding OSA-HA, at 1, 2.5 and 5 mg/ml, to a suspension of TA in bidistilled water 
(100 μg/ml). A suspension of TA in bidistilled water at the same concentration (100 
μg/ml) was used as control. In all the solutions the excess of TA was present and 
visible at the bottom of the vials. 
 
5.2.3 Dissolution tests  
Dissolution tests were performed by using the solutions prepared. At scheduled time 
intervals (2, 4, 6, 24, 48 hrs), the solutions were centrifuged (1200 rpm for 15 min) in 
order to eliminate the unloaded drug and supernatant analyzed by means of reversed-
phase high-performance liquid chromatography (RP-HPLC) (figure 5.1). 
 
 
Figure 5.1: Schematic representation of OSA-HA micelles formation and 
triamcinolone encapsulation 
 
The chromatograph was equipped with a HPLC LC-10AD pump (Shimadzu, Milano, 
Italy), a 7725i injection valve (Rheodyne), a SPV-10A UV-vis detector (Shimadzu) set 
at the wavelength of 254 nm and a C-R6A integrator (Shimadzu). RP-HPLC 
experiments were carried out using a Luna C18 (150 × 4.6 mm) column (Phenomenex, 
Klwid, USA). The mobile phase was a mixture of water and acetonitrile (50:50 v/v). 
The flow rate was set at 1 mL/min, and the stop time was 10 min. The results were 
averaged on three independent batches. The experiments were run in triplicate. 
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5.2.4 Release kinetics 
As for the in vitro release kinetics of TA from OSA-HA-based gels, they were 
evaluated by immersing dialysis membranes (Spectra/Por Biotech Cellular ester, 
molecular cut off: 12 kDa) loaded with 5 ml of gels in 80 ml of PBS at 37 °C. At 
scheduled time intervals, the release medium was withdrawn, replaced with the same 
volume of fresh medium, and analyzed by reversed-phase high-performance liquid 
chromatography (RP-HPLC). 
The release data were fitted to the following semiempirical equations, adapted from 
methods reported in literature and describing drug release from HA-based systems as 
the result of a dissolutive and a Fickian diffusional mechanisms [19-20]. 
The dissolutive contribution is expressed by: 
 ܨௗ௜௦௦ ൌ ܨௗ௜௦௦ǡஶ ȉ ݇ௗ௜௦௦ ȉ ݐ଴Ǥହ                    (5.1) 
 
where ܨௗ௜௦௦ and ܨௗ௜௦௦ǡஶ are the drug fractions released by dissolution at time t and 
after an infinite time, respectively, ݇ௗ௜௦௦ is the kinetic dissolution parameter. The 
diffusional contribution to drug release is given by: 
 ܨௗ௜௙௙ ൌ ൫ͳ െ ܨௗ௜௦௦ǡஶ൯ ȉ ቀͳ െ ݁ݔ݌൫െ݇ௗ௜௙௙ ȉ ݐ൯ቁ                 (5.2) 
 
Here ܨௗ௜௙௙ is the drug fractions released due to diffusion at time t and ݇ௗ௜௙௙ is the 
kinetic diffusional parameter. The overall released fraction is given by the sum of 
diffusional and dissolution contributions, i.e.: 
 ܨ ൌ ܨௗ௜௦௦ ൅ ܨௗ௜௙௙ ൌ ൫ܨௗ௜௦௦ǡஶ ȉ ݇ௗ௜௦௦ ȉ ݐ଴Ǥହ൯ ൅ ൬൫ͳ െ ܨௗ௜௦௦ǡஶ൯ ȉ ቀͳ െ ݁ݔ݌൫െ݇ௗ௜௙௙ ȉ ݐ൯ቁ൰
     (5.3) 
5.3 RESULTS and DISCUSSION 
 
5.3.1 Dissolution tests 
 
In figure 5.2 an example of plot from HPLC measurement was reported. 
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Figure 5.2: Example of HPLC measurement 
 
In Figure 5.3 the results of the dissolution tests were reported as the concentration of 
TA found into the supernatant of the solutions prepared with different amount of 
OSA-HA (see Methods section) normalized to the water solubility of TA as a function 
of time. As it can be seen from the figure, after 48 hrs all the solutions reach an 
equilibrium solubility value. In particular, the value of TA solubility in water was 
found to be 18 μg/ml according to literature data [21]. In the presence of OSA-HA in 
the solutions the TA concentration in the supernatant was found to increase as a 
function of OSA-HA concentration. In detail, in the presence of 0.1% w/v of OSA-HA 
the observed TA concentration was 4-fold higher compared to TA saturation 
concentration in water when OSA-HA concentration is 0.5%w/v. These results 
demonstrate the inclusion capability of OSA-HA towards TA. 
 
 
Figure 5.3: Normalised solubilisation profiles of TA. 
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5.3.2 Release kinetics 
 
Experimental and simulated in vitro fractional release profiles of TA from OSA-HA 
platforms in phosphate buffer were shown in figure 5.4. The release of the loaded TA 
could be sustained for at least 7 days. As shown in the graphs reported in figure 5.4, a 
24h-burst effect was noticed in all cases. In particular, the burst fraction was found to 
be decreasing with increasing OSA-HA concentration and the released drug fractions 
after 24 h were 0.835, 0.782, 0.695 and 0.571 for TA suspension, from 1, 2.5 and 5.0 
mg/mL OSA-HA solutions, respectively. 
Moreover, the applied model allowed to discriminate the diffusive and dissolution 
contributions to drug release. Experimental data were well fit by model equation. In 
the case of blank experiments (i.e. free TA released from solution loaded in dialysis 
membrane), the results of the model showed that TA is released from the membrane 
mainly by diffusion, as expected taking into account the poor solubility of the drug. It 
must also be underlined that an increase of the concentration of OSA-HA in the 
membrane led to increasing fractions of TA released by dissolution, as indicated by 
the increasing values of ܨௗ௜௦௦, (table 5.1). 
These results confirm the solubility enhancement of the modified HA towards the 
hydrophobic TA. Furthermore, it should be noted that the kinetics of diffusion appears 
to be basically the same, irrespective of the OSA-HA concentration [22]. Actually, ݇ௗ௜௙௙ values were variable between 0.230 h-1 in the case of free TA and 0.198 h-1 for 
the OSA-HA solution at 5.0 mg/mL, as expected in the case of the diffusion of low 
molecular weight molecules through the hydrated matrix of a polymeric solution. 
Therefore, release data clearly show that a combined mechanism, based on parallel 
dissolution and diffusion, governs TA release from OSA-HA-based solution. The 
analysis of release profiles reported in Figure 5. shows that, in all cases, diffusion is 
faster compared to dissolution, i.e. that at least initial release phases are governed by 
diffusion. The dissolution-controlled mechanism of TA released from the inner layer 
was regarded as secondary, slower release. 
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Figure 5.4: TA release profiles from water suspension and OSA-HA solutions at 
different concentration: (A) TA suspension in water; (B) OSA-HA 0.1 % w/v (C) 
OSA-HA 0.25 % w/v; (D) OSA-HA 0.5 % w/v. Solid lines represent model 
simulations. Fitting was performed by Eq.5.3 
 
 Free TA 
OSA-HA  
1.0 mg/mL 
OSA-HA  
2.5 mg/mL 
OSA-HA  
5.0 mg/mL ܨௗ௜௦௦ǡஶ 0.238 ± 0.078 0.313 ± 0.031 0.473 ± 0.182 0.657 ± 0.272 ݇ௗ௜௦௦, h-1/2 0.0808 ± 0.0030 0.0783 ± 0.0037 0.0738 ± 0.0055 0.0795 ± 0.0071 ݇ௗ௜௙௙, h-1 0.230 ± 0.018 0.241 ± 0.068 0.212 ± 0.100 0.198 ± 0.066 
 
Table 5.1: Model parameters as calculated by fitting experimental release data to Eq. 
(5.3). 
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5.4 CONCLUSIONS 
 
In this study it was demonstrated that a novel amphiphilic high molecular weight HA 
derivative and, in particular, an octenyl succinic anhydride (OSA) modified HA 
(OSA-HA) is able to self-assemble into micelles, load a hydrophobic drug and release 
the active molecule with a controlled kinetic mechanism. 
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CHAPTER 6 
 
Hyaluronic Acid Based Hydrogels For Regenerative Medicine 
Applications 
 
ABSTRACT 
 
HA hydrogels, obtained by crosslinking HA molecules with divinyl sulfone (DVS) and 
based on a simple, reproducible and safe process that does not employ any organic 
solvents, were developed. Owing to an effective purification step, the resulting 
homogeneous hydrogels do not contain any detectable residual crosslinking agent and 
are easier to inject through a fine needle. 
HA hydrogels were characterized in terms of their viscoelastic and network structural 
properties. They exhibit a rheological behavior typical of a strong gel and show 
improved viscoelastic properties by increasing HA concentration and decreasing 
HA/DVS weight ratio. Furthermore it was demonstrated that processes such as 
sterilization and extrusion through clinical needles do not imply significant alteration of 
viscoelastic properties. Moreover  the crosslinks appear to compact the network, being a 
reduction of the mesh size by increasing the crosslinker amount. In vitro and in vivo HA 
hydrogel degradation tests demonstrated that these new hydrogels show a good stability 
against enzymatic degradation, that increases by increasing HA concentration and 
decreasing HA/DVS weight ratio. Finally the hydrogels show a good biocompatibility 
confirmed by in vitro and in vivo tests.  
 
 
6.1 INTRODUCTION 
 
Hydrogels thanks to their unique properties such as excellent biocompatibility,  high 
water content and capacity to degrade in safe product, have attracted a great deal of 
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attention and have been extensively used in several biomedical applications such as 
regenerative medicine and drug delivery [1-3]. 
Hyaluronic acid (HA), also referred to as hyaluronan, is a naturally occurring linear 
polysaccharide composed of repeating disaccharide units of D-glucuronic acid and N-
acetyl-D-glucosamine linked by β-1-3 and β-1-4 glycosidic bonds [4-8].  
HA is a primary component of the extra-cellular matrix of the mammalian connective 
tissues. It is an important structural element in the skin and is present in high 
concentration in the synovial joint fluids, vitreous humor of the eyes, hyaline cartilage, 
disc nucleus and umbilical cord [9-13]. HA plays a major role in several functions in 
vivo such as lubrification of arthritis joints, viscoelastic properties of soft tissue and it is 
involved in important cell functions such as cell motility, cell matrix adhesion and cell 
organization [14-18].  
In biological tissues it has a very high molar mass, usually in the order of millions of 
Daltons, and possesses interesting visco-elastic properties based on its polymeric and 
polyelectrolyte characteristics [19]. 
Thanks to its biocompatibility, physical, chemical and biological properties and due to 
the ease of chemical functionalisation, HA has generated increasing interest among 
researchers and it is already used in several biomedical applications [20-22].  
Clinically, HA is used in soft tissue replacement and augmentation and in surgical 
procedures and diagnostic. It is employed as a diagnostic marker for many disease states 
including cancer, rheumatoid arthritis, liver pathologies, and as an early marker for 
impending rejection following organ transplantation. It is also used for supplementation 
of impaired synovial fluid in arthritic patients, in aesthetic medicine such as dermal 
fillers, in soft tissue surgery such as vocal fold augmentation, as scaffold for tissue 
engineering applications and as a device in several surgical procedures, particularly as 
antiadhesive following abdominal procedures and as aid in cataract surgery [23-24]. 
In order to be used for the mentioned application, HA can be obtained from different 
sources, mainly by extraction from different tissues such as umbilical cord, rooster 
comb, synovial fluid and vitreous humor; this procedure, however, is expensive and 
requires an extensive purification of the crude product [25-26]. For these reasons 
alternatives to the animal extraction of HA were gradually replacing by industrial 
techniques based on microorganism fermentation. In large industrial quantities, HA is 
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produced by fermentation of strains of bacteria Streptococci. However Streptococcus 
requires an expensive and very difficult fermentation, the use of substantial volumes of 
organic solvents, and finally the HA product can contain endo- and exotoxins. The HA 
industrial manufacturing is recently devoted to the fermentation of Bacillus subtilis [27] 
that represents a valid alternative to Streptococcus HA production because it is a non-
pathogenic microorganism and the final HA product does not contain any endo- or 
exotoxins; moreover it’s possible to have a better control on HA molecular weight 
(MW) and also Bacillus subtilis grows on minimal media in contrast to Streptococcus 
that requires more expensive and complex media for growth. 
Although HA is an excellent biocompatible material, when native HA is injected in 
physiological environment, a fast degradation process often occurs because from a side 
it has a high affinity for water molecules and from the other side it is degraded in vivo 
by hyaluronidase. For this reason, different strategies such as crosslinking or 
coniugation, have been used to stabilize HA and obtain a more stable material 
maintaining at the same time its fundamental properties [28-34]. In the case of 
crosslinking, HA reacts with a crosslinking agent that is capable of creating covalent 
bonds between HA chains, instead in the case of coniugation a compound is grafted 
onto HA chain. 
Chemical modifications of HA, by means of both crosslinking or coniugation, generally 
involve HA carboxyl or hydroxyl groups. Concerning the modification of the carboxylic 
groups, an example of crosslinker agent used to obtain HA hydrogels is 1-ethyl-3-[3-
(dimethylamino)-propyl]-carbodiimide (EDC), one of the preferred among the 
carbodiimide because of its water solubility [35]. The EDC reacts with the HA 
carboxylic acid forming an O-acyl isourea-HA intermediate, which in turn react with 
the chosen amine to form the amide bond. However the O-acyl isourea intermediate is 
very reactive and can hydrolyze and then rearrange into a stable N-acyl urea by-product. 
For this reason dimethyl sulfoxide (DMSO) methodologies on the acidic form of the 
HA have been developed to minimize the EDC hydrolysis [36].  
Furthermore different esters and amides of HA, involving carboxyl groups 
modifications, have been used to form hydrogels for biomedical applications. For 
example esterification of the carboxyl groups of HA with different alcohol residues 
resulted in a series of derivatives named HYAFF® [37]. Examples of amides of HA are 
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HYADD®, obtained derivatizing the polysaccharide backbone with alkylic side chains 
through amide bonds [38]. 
As regards to the modifications involving the -OH groups, crosslinked HA hydrogels 
are obtained using crosslinker agents such as butanediol-diglycidyl ether (BDDE) or 
divinyl sulfone (DVS) [39]. Furthermore UV-light photocrosslinking hydrogels can be 
realized through  methacrylate–HA conjugates [40], while in situ HA chemical 
crosslinked hydrogels can be obtained from thiol-modified HA [41]. 
The modifications methods currently available to crosslink or conjugate HA molecules 
present some drawbacks. In particular the modification involving HA carboxyl groups 
can alter the distribution of negative charges along the polymer chain, affecting some 
fundamental HA biological properties [42]. Furthermore, numerous methods have been 
developed in organic solvents, such as DMSO or also dimethylformamide (DMF). In 
this case, the native HA, which is in the form of a sodium salt, needs to be in its acidic 
form or a tetra-butylammonium salt (HA-TBA) for solubilization in organic solvents 
and this requires additional steps of physical and chemical treatments that can induce 
HA chain hydrolysis [43-44].  
As regards to the hydrogels obtained by crosslinking reactions, the degree of 
modification, which is referred to as the crosslinking degree, has a significant effect on 
the properties of a crosslinked biomaterial, typically in the form of a gel. As the 
crosslinking density of a gel increases, the distance between the crosslinked segments 
becomes shorter. When a load is applied, these shorter segments require a greater force 
to deflect. Thus, increasing the crosslinking density strengthens the overall network, 
thereby increasing the hardness or stiffness of the gel. However, when the gel comprises 
all or mostly pendant HA polymer chains, a low crosslinking density network is formed 
which results in softer gels. 
The crosslinking degree strongly affects the injectability of the hydrogel through 
pharmaceutical needles, a fundamental property to consider in the design of hydrogel to 
use it for several biomedical applications. In particular a low crosslinking degree 
determines a soft gel, implying a good injectability, but an high in vivo degradation rate 
of the gel; on the other side an high crosslinking degree determines an increasing of the 
gel hardness and so a low injectability profile, but it is required in order to have gels 
with good mechanical properties and with an increased residence time. 
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HA concentration is another parameter that influences significantly the injectability 
profile of the hydrogel. In particular by increasing HA concentration, the hardness or 
stiffness of the gel increase, so it is necessary to vary opportunely the polymer 
concentration in order to obtain an hydrogel with specific requirements to be used for 
biomedical applications. 
Furthermore hydrogel injectability depends also from the molecular weight distribution 
of the polymer that strongly affects the homogeneity of the system. 
The aim of this work was to produce HA based hydrogels with improved injectability 
profile while maintaining the mechanical properties.   
The design of HA hydrogels requires to consider many parameters such as HA source, 
HA concentration, buffer environment for the hydrogel, nature of the crosslinking agent, 
crosslinking agent/HA weight ratio. However, regardless of these elements, the purity 
of the HA raw material and the safety of the crosslinking technology are crucial 
elements in achieving a hydrogel that can be safely administered to patients. 
For these reasons in this work HA produced by fermentation of the novel, superior and 
safe strain, namely Bacillus subtilis, has been used to produce hydrogels. This 
production technology affords a HA product with unique advantageous properties such 
as reproducible molecular weight. In addition, the higher purity of Bacillus-subtilis 
derived HA compared to the available sources of HA offers the possibility of heat 
sterilization with minor degradation under given conditions and allows its use with 
various ingredients without degradation or decrease in viscosity.  
Moreover the hydrogels were produced according to the method described in [45] using 
divinyl sulfone (DVS) as the crosslinking agent and based on a simple, reproducible and 
safe process that does not employ any organic solvents. Owing to an effective 
purification step, the resulting homogeneous hydrogels do not contain any detectable 
residual crosslinking agent. Furthermore the crosslinking reaction with DVS involves 
hydroxyl groups of HA molecular backbone, avoiding the problems related to the 
modification reactions involving HA carboxyl groups. 
So in this frame the aim was to produce cross-linked HA hydrogels with improved 
properties, such as higher homogeneity and increased softness compared to the standard 
DVS crosslinked HA-hydrogels and an easier syringeability. The hydrogels were 
characterized in terms of viscoelastic properties as function of HA concentration and 
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HA/DVS weight ratio (w.r.) and network structural parameters. Moreover hydrogel 
degradation and biocompatibility in vitro and in vivo were studied. 
 
6.2 MATERIALS AND METHODS 
 
6.2.1 Materials  
 
HA used in this work is produced by Novozymes Biopharma A/S by fermentation of the 
novel, superior and safe strain Bacillus subtilis. The weight-average molecular weight 
of HA was determined by size exclusion chromatography combined with multi angle 
laser light scattering detection (SEC-MALS). Molecular weight of the starting materials 
was in the range of 0.7 to 1.0 MDa. 
DVS was obtained from Merck Gmbh and Sigma Aldrich Co. Hyaluronidase (HAase) 
from bovine testes was purchased from Sigma Aldrich Denmark A/S (ref H3506). 
Phosphate buffer saline (PBS) tablets without calcium and magnesium were obtained 
from MP Biomedicals Inc. (France). 
 
6.2.2 Hydrogel preparation  
  
HA was crosslinked according to the method described in [45] and here briefly 
summarized. The method consists of the following steps: (a) preparation of an alkaline 
solution of HA; (b) adding DVS to the solution of step (a), whereby HA is crosslinked 
with the DVS to form a gel; (c) the solution temperature in step (b) is heated to a 
temperature of 45°C for 180 minutes preferably without stirring.  
It was demonstrated that a heating step was beneficial after addition of the DVS to the 
solution. The hydrogels were prepared with two different HA starting concentrations 
(5% and 6%) and three different HA/DVS weight ratios (2.5:1, 5:1 and 8:1, which 
corresponds to crosslinking degrees of 40, 20 and 12.5 w/w% and 80, 40 and 25 mole%, 
respectively). The hydrogels were prepared by dissolving HA in aqueous NaOH and 
then adding DVS.  
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6.2.3 Viscoelastic and Injectability properties  
 
Viscoelastic properties of the hydrogels have been evaluated on a rotational rheometer 
(Gemini, Bohlin Instruments, UK) using a parallel plate geometry (PP30 cell).  
Hydrogel was subjected to periodic oscillation in a dynamic experiment (Small 
amplitude frequency sweep tests) to evaluate the dependence of the viscoelastic 
parameters, such as the elastic and viscous moduli, G’ and G’’, upon the frequency.  
In dynamic experiment the material is subjected to a sinusoidal shear strain: 
 
 ϒ=ϒ 0 sin (ω t)                                                                                                            (6.1) 
 
where ϒ0 is the shear strain amplitude, ω is the oscillation frequency (which can be also 
expressed as 2πf where f is the frequency in Hz) and t the time. The mechanical 
response, expressed as shear stress τ of viscoelastic materials, is intermediate between 
an ideal pure elastic solid (obeying to the Hooke's law) and an ideal pure viscous fluid 
(obeying to the Newton's law) and therefore is out of phase respect to the imposed 
deformation as expressed by: 
τ =G’(ω) ϒ0 sin (ω t) +G”(ω) ϒ0 cos (ω t)                                                                   (6.2) 
 
where G'(ω) is the shear storage modulus or elastic modulus and G"(ω) is the shear loss 
modulus or viscous.  
G' gives information about the elasticity or the energy stored in the material during 
deformation, whereas G" describes the viscous character or the energy dissipated as 
heat. In particular, the elastic modulus gives information about the capability of the 
sample to sustain load and return in the initial configuration after an imposed stress or 
deformation [46]. 
The ratio between the viscous modulus and the elastic modulus is expressed by the loss 
tangent:  
 
tanδ=G’’/G’                                                                                                                 (6.3) 
 
where δ is the phase angle. 
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The loss tangent is a measure of the ratio of energy lost to energy stored in the cyclic 
deformation. The phase angle, δ, is equal to 90° for a purely viscous material, 0° for a 
pure elastic material, and 0°<δ<90° for viscoelastic materials [47]. 
The frequency range investigated was 0.01Hz-1 Hz. In order to identify the linear 
viscoelastic response range of the materials, preliminary strain sweep tests were 
performed on the samples, at the oscillation frequency of 1 Hz. The tests were repeated 
at least three times on each sample. 
The tests have been carried out at the controlled temperature of 25°C by using a 
thermostatic bath. In order to avoid water evaporation, the humidity of the chamber 
containing the samples has been controlled by a humidity control accessory. 
In order to evaluate the effect of sterilization process on the viscoelastic parameters, the 
oscillation tests were repeated on sterile samples, which were obtained by autoclaving at 
standard condtions (121°C, 15 min).  
The effect of injection through needle was evaluated by performing the test on injected 
samples (gauge length, 22G*1” (1”) 22G*11/2” (11/2”) ). 
The syringeability was measured on a Texture analyZer (Stable Micro Systems, TA. XT 
Plus) as the force (in N) needed to inject the hydrogel through a 27G1/2 needle over a 
distance of 55 mm at a speed of 12.5 mm/min (0.2 mL/min) using 1 mL syringes.  
Cross-linked HA hydrogel with HA concentration of 6% and HA/DVS weight ratio of 
8:1 was considered and the test was repeated three times. 
Moreover the syringeability of DVS crosslinked HA hydrogels prepared according to 
the patent [45] was compared to that of hydrogels prepared according to traditional 
methods, for example  that not present heating step in the hydrogels preparation. 
 
6.2.4 Small Angle Neutron Scattering (SANS) 
 
The SANS studies were performed on samples characterized by HA concentration of 
6% and crosslinker percentage of 1% and 10%, using a LOQ beam line with an ISIS 
pulsed neutron source. The LOQ beam employs neutrons at wavelengths (l ) ranging 
from 2.2 to 10 Å, which are detected by time-of-flight analysis and recorded with a 64-
cm2 two-dimensional detector placed at 4.1 m from the sample. Such a setup allows 
collecting data of scattering vector modulus ( )4 sin 2Q p l q=  in an interval ranging 
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from 0.006 to 0.32 Å–1  [49], where q  is the scattering angle. The samples studies were 
contained in 1-mm path length, Hellma quartz cells at 25 °C. The experimental raw data 
were converted on absolute intensity following a previously reported procedure [49].  
 
6.2.5 In vitro degradation 
 
In vitro tests were performed to evaluate hydrogel degradation. A stock solution of 
hyaluronidase was prepared from a starting solution of 100 mg/mL of HAase in PBS 
(43.900 Units/mL). This solution was diluted to a concentration of 43.9 Units/mL and 
stored at T= -20°C prior to use. The hydrogel sample was mixed by vortex with an 
HAase solution in volume ratio of  10:1  to obtain a final enzyme concentration of 4 
Units/mL and incubated at T=37° C for different incubation times to analyze the 
dependence of degradation properties upon time. In order to verify the absence of 
degradation phenomena due to temperature, a degradation test was carried out on 
control samples mixed with  PBS and incubated at T=37 °C. Rheological oscillation 
tests were carried out immediately and after 3h, 9h, 16h and 24h. The degradation was 
evaluated by measuring G’/G’0 at a frequency of 0.1 Hz as function of time. G’0 is the 
G’ value just after the mixing with HAase solution.  
 
6.2.6 Biological properties 
 
6.2.6.1 Vitality and Proliferation    
Mouse embryonic fibroblast  NIH3T3 cells  were cultured in  Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal calf serum (Gibco-BRL Life 
Technologies, Italy) and antibiotics (penicillin G sodium 100 U/mL, streptomycin 100 
g/mL, Euroclone) at 37 °C and 5% CO2. 
For seeding on hydrogels, the cells were washed with phosphate-buffered saline (PBS) 
and incubated with trypsin-EDTA (0,25% trypsin,1m M EDTA, Euroclone), for 5 
minutes at 37°C, re-suspended in fresh medium and statically seeded with hydrogel 
(30.000 cells/cm2). The cells were cultured for 1 and 4 days.  
Cell viability was evaluated by using Alamar Blue (AB) assay. AB  was added to the 
samples (10% v/v of medium) and incubated at 37 °C for 4h.The absorbance of the 
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samples was measured using  an spectrophotometer plate reader  (multilabel counter, 
1420 Victor, Perkin Elmer) at 570 nm and 600 nm. 
AB is an indicator dye that incorporates an oxidation-reduction indicator that changes 
colour in response to the chemical reduction in growth medium, resulting from cell 
viability. Data are expressed as the percentage difference in reduction between treated 
and control cells in viability assay: 
 
Percentage difference between treated and control cells = (O2 x A1) - (O1 x A2)/ (O2 x 
P1) - (O1 x P2) x 100                                                                                             (6.4) 
where O1 is the molar extinction coefficient (E) of oxidized alamarBlue® (Blue) at 
570nm; O2 is the E of oxidized alamarBlue® at 600nm; A1 is the absorbance of test 
wells at 570nm; A2 is the absorbance of test wells at 600nm; P1 is the absorbance of 
positive growth control well (cells plus alamarBlue® but no hydrogel) at 570nm; P2 is 
the absorbance of positive growth control well at 600nm. 
For proliferation tests, total  DNA content of NIH3T3 cells/hydrogel was assessed at 1,4 
days with Quant-iT™ PicoGreen® dsDNA reagent Kit. The PicoGreen dye binds to 
dsDNA and the resulting fluorescence corresponds to the concentration of dsDNA in 
solution.The  total  DNA  was extracted  from each sample by incubating the cell layer 
in 500 µl of cell lysis solution (0.2% v/v Triton X-100, 10 mM Tris (pH 7.0), 1 mM 
EDTA) for 1h-70°C,then followed by three cycles of freeze and thaw;and assayed by 
following manufacturer ‘s  instruction  (Molecular Probes, Cat # P-7589). DNA content 
was determined fluorometrically at excitation wavelength of 480 nm and emission 
wavelength 528 nm using a microplate reader (Perckin Elmer Victor microplate reader). 
The relative fluorescence units were correlated with the number of cells present in the 
hydrogels. 
 
6.2.6.2 Stem cell differenziation  
    
The osteogenic differentiation of hMSCs was evaluated by DNA/alkaline phosphatase 
(ALP) activity measurement. For the DNA/ALP test, at predetermined time point the 
hydrogels were washed twice with ice-cold PBS, transferred to centrifuge tubes 
containing 300 mL cell lysis buffer (10mM Tris-HCL, 10mM NaH2PO4/NaHPO4, 
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130mM NaCl, 1% Triton X-100, and 10mM sodium pyrophosphate; BD Biosciences), 
and lysed at -4°C for 45 min. After 5 min of centrifugation, total amount of DNA was 
detected using Pico Green Assay (Molecular Probes), while ALP activity was measured 
using a biochemical assay (SensoLyte pNPP ALP assay kit; ANASPEC). 
 
6.2.6.3 In vivo study     
 
To study in vivo properties HA hydrogels characterized by HA concentration of 5% and 
HA/DVS w.r. of 5:1 and  HA/DVS w.r. of 8:1 were prepared. HA-DVS hydrogels were 
mixed with physiological saline with a volume ratio of 1:1. After the hydrogels were 
completely homogenized with a homogenizer (T-18 basic, IKA, Tokyo, Japan) at 8000 
rpm for 5 min, 1 mL of the hydrogel suspension was injected into the subcutaneous 
dorsum of the mice. As a control, non-modified HA solution was used. 
Male Sprague-Dawley rats (3 rats/test group) were anesthetized with ketamine 
hydrochloride (8 mg/kg body weight) and xylazine hydrochloride (1.15 mg/kg body 
weight). After the injection of HA hydrogels, the rats were sacrificed in 1, 6, and 21 
days, and the HA hydrogels were retrieved. General condition of the rat such us body 
weight and gel implant size were monitored. Furthermore erythema and edema of skin 
and tissue around injection site were scored. 
 
6.3 RESULTS and DISCUSSION 
6.3.1 Hydrogels viscoelastic and injectability properties  
In figure 6.1 the dependence of the elastic and the viscous moduli upon the oscillation 
frequency, the so-called mechanical spectra, for the gels obtained crosslinking HA with 
DVS was reported; in particular as an example the mechanical spectra of hydrogel with 
a HA concentration of 5% and an HA/DVS weight ratio of 8:1 was reported.  
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Figure 6.1: Mechanical spectra of samples characterized by HA/DVS 8:1 and 
[HA]=5%  
 
From the mechanical spectra, it can be noticed that the elastic modulus is one order of 
magnitude higher than viscous modulus, G’ is almost independent of frequency and tan 
δ is in the range 0.01-0.1. These samples behave as strong gel materials.  
The overall rheological response is due to the contributions of physical crosslinks, such 
as electrostatic interactions and hydrogen bonds, chemical crosslinks such as covalent 
bonds, and to topological interactions among the HA macromolecules (entanglements). 
The crosslinks and entanglements bring about a reduction of the intrinsic mobility of the 
polymer chains that are not able to release stress; consequently the material shows a 
predominant elastic behavior (G’>G”) and behaves as a three dimensional network 
where the principal mode of accommodation of the applied stress is by network 
deformation. 
Changing HA/DVS weight ratio and HA concentration, the gels still behave as strong 
gels, but their rheological properties differ quantitatively. In table 6.1 the viscoelastic 
properties for the gels at frequency of 0.1 Hz were reported.  
In fig. 6.2 the mechanical spectra of samples prepared at the same HA concentration 
(5%) and at different HA/DVS weight ratio (2.5:1; 5:1; 8:1) were reported. Comparing 
the results for the three strong gels, it can be observed that the highest elastic modulus 
was obtained in the case of samples characterized by a HA/DVS w.r. of 2.5:1. In 
particular when HA/DVS w.r. is 2.5:1 at a frequency of 0.1 Hz G’ is 304.30 Pa, while 
for the strong gel at HA/DVS w.r. of 5:1. the elastic modulus is 56.20 Pa and for the 
strong gel at HA/DVS w.r. of 8:1 G’ is 25.02 Pa (table 6.1). By doubling the weight 
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ratio (from 2.5:1 to 5:1), G’ is 5.4 times lower while by raising 1.6 times the weight 
ratio (from 5:1 to 8:1) G’ is 2.25 times lower. The decrease of the starting HA/DVS 
weight ratio leads to gels with improved viscoelastic properties because the elastic 
modulus is proportional to the number of crosslinking points, that increase with the 
increasing of the amount of crosslinker. 
 
[HA] 
[%] 
HA/DVS 
w.r 
Viscoelastic properties @ 0.1 Hz 
G' [Pa] G'' [Pa] η* [Pas]  tanδ 
5 
2.5:1 304.30 16.10 485.20 0.058 
5:1 56.02 3.74 89.36 0.067 
8:1 25.02 2.76 40.10 0.12 
6 
2.5:1 468.43 17.7 585.48 0.038 
5:1 165.85 9.05 239.17 0.055 
8:1 42.45 3.18 67.76 0.075 
Table 6.1: Viscoelastic properties for the gels at frequency of 0.1 Hz 
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Figure 6.2: Mechanical spectra of samples at different HA/DVS weight ratio (2.5:1; 
5:1; 8:1) 
 
Also varying the starting HA concentration, the viscoelastic properties of the gels 
change significantly. In particular the viscoelastic properties increase with increasing of 
HA starting concentration for any HA/DVS weight ratio (fig. 6.3a, fig.6.3b, fig.6.3c).  
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Figure 6.3 a 
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Figure 6.3 b 
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Figure 6.3 c 
Figure 6.3: The mechanical spectra  of samples at different HA concentrations and 
HA/DVS weight ratio: 6.3 a) the comparison of the mechanical spectra of samples 
characterized by [HA]=5% and 6% and  HA/DVS weigth ratio of 2.5:1; 6.3 b) the 
comparison of the mechanical spectra of samples characterized by [HA]=5% and 6% 
and  HA/DVS weigth ratio of 5:1; 6.3 c) the comparison of the mechanical spectra of 
samples characterized by [HA]=5% and 6% and  HA/DVS weigth ratio of 8:1. 
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In particular for samples prepared with HA/DVS w.r. of 2.5:1, G’ is 304.30 Pa when 
HA concentration is 5%, while it is 1.5 times higher (468.43 Pa) when HA 
concentration is 6%. For samples characterized by HA/DVS w.r of 5:1 it can be 
observed that for HA concentration of 5% G’ is 56,2 Pa, while for HA concentration of 
6% G’ is 165,85 Pa that is about 3 times higher. When HA/DVS w.r is 8:1 for HA 
concentration of 5% G’ is 25,02 Pa while for HA concentration of 6% G’ is 42,45 Pa 
that is about 1.7 times higher. By decreasing the weight ratio, the effect of concentration 
becomes stronger. To analyze the effect of processing such as sterilization and injection 
through needle on hydrogels, oscillation tests on sterile and not sterile samples, before 
and after injection were performed.  
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Figure 6.4: Effect of sterilization and injection on mechanical properties: 6.4a) the 
comparison of the mechanical spectra of samples before and after sterilization; 6.4 b) 
the comparison of the mechanical spectra of samples before and after injection through 
different needles. 
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In fig. 6.4 a the comparison between the mechanical spectra of the sterile and not sterile 
samples were reported. There is not statistical significant difference between the 
dynamic moduli before and after sterilization, so it can be concluded that the 
sterilization process does not affect the hydrogel viscoelastic parameters. In fig. 6.4 b 
the mechanical spectra of the sterilized samples are compared before and after the 
injection through two different needles having different gauge length, G*1” (named 1”) 
and G*1”1/2 (named 1”1/2). It can be noticed that also the injection through the needles 
does not have effect on the viscoelastic parameters. 
In figure 6.5 the comparison between the syringeability of the new DVS cross-linked 
HA hydrogels (characterized by HA concentration and HA/DVS weight ratios of 8:1), 
prepared according the patent [45], and that of hydrogels prepared according to 
traditional methods was shown. 
The figure 6.5 shows that the force needed to inject the new hydrogel is lower than 
hydrogels prepared according to traditional methods. 
Furthermore injection profile shows that there is a better stability of the applied 
injection force in the case of the new hydrogels than those prepared according to 
traditional methods. 
 
 
 
Figure 6.5: Comparision of injectability properties of new crosslinked HA hydrogels 
(new) and hydrogel prepared with traditional methods (old) 
 
old  
new  
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Since the stability of injection force is index of the sample homogeneity, the results 
demonstrated that the new hydrogels were more homogeneous than those obtained with 
traditional methods and were easier to inject through a fine needle. 
6.3.2 Network Structural Parameters 
The values of the elastic modulus can be used to estimate the parameter of  the network 
structure [50]. 
As G is proportional to the number of entanglements [47], the elastic modulus can be 
expressed through: 
 
zTRG ××@                         (6.5) 
  
where RT is the thermal energy and z is the number of the entanglements points or 
crosslinking point expressed in mol/volume.  
The parameter z can be calculated by: 
e
M
c
z »                       (6.6) 
 where c is the polymer concentration and Me is the average molecular weight of the 
polymer segments between two entanglements. 
Substituting in eq.(6.5), Me can be estimated by the following equation: 
 
G
cTR
M e
××
@           (6.7) 
To calculate G by means of eq.(6.7), it has to be assumed the validity of the rubber 
elasticity theory and that the temporary network of gel–like material is presumed to 
behave as does vulcanized rubber upon stimulus of a time scale shorter than the life 
time of the entanglement network [51].  
As the “dangling ends”, which are the polymer chain segments attached to the network 
by only one entanglement point, do not contribute to the G value,  because they cannot 
store elastic energy, a correction is needed in eq.(6.7) [51]:   
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where Mn is the number average molecular weight.  
Using the “equivalent network model” [52], it is possible to give an estimation  DN 
which is the average distance between the entanglements points or crosslinking points, 
in a idealized “equivalent network”: 
 
3
6
Ac
M
D eN ××
×
=
p
         (6.9) 
 
where A is the Avogadro’s number.  
 
In table 6.2 the results in terms of DN and Me were reported. It can be noticed that the 
highest Me (238292 g/mol) and highest Dn (38 nm) were displayed by sample having 
the lowest starting concentration and the lower density of crosslinker (HA concentration 
of 5% and a HA/DVS w. r. of 8:1). Indeed the sample that shows the lowest Me (61213) 
and a Dn of 24 nm, is characterized by the highest starting concentration and the highest 
crosslinker amount (HA concentration of 6% and a HA/DVS w. r. of 2.5:1).  
 
 
[HA] 
[%] 
HA/DVS 
w.r 
G* 
[Pa] 
Me 
 (g/mol) 
DN 
 (nm) 
Degradation 
level 
[%] 
 2.5:1 304.30 97104 26 42 
5 5:1 56.02 208107 34 69 
 8:1 25.02 238292 38 77 
 2.5:1 468.43 61213 24 35 
6 5:1 165.85 110457 31 68 
 8:1 42.45 203958 38 72 
Table 6.2: Network parameters for HA-DVS crosslinked hydrogels 
* value of the elastic modulus at 0.1 Hz 
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6.3.3 SANS results 
 
Figure 6.6 reports the scattering intensities ( )I Q for HA hydrogels, without crosslinks 
and at 1% and 10% of crosslinks.  
Analysis of HA crosslink-free sample reveals a quite flat profile, suggesting a very 
weak network. Indeed, the scattering should arise from the polymer chains that, because 
of the low concentration and the high level of solvation, is observed to appear flat. The 
situation is different in the presence of crosslinks. According to the mean-field theory of 
polymers in a good solvent [51, 53-54], scattering profile can be described in terms of 
the mesh size formed by crosslinks. It arises from the thermal fluctuations of the 
polymer concentration and is related to the average distance between crosslinks (the 
mesh size ξ): in this case in the region where 1qx <<  the scattering intensities ( )I Q  
can be well described by a Lorentzian function: 
 
( )
0
2 21
I
I Q
Q x
=
+
           (6.10) 
where 0I  is the limit value of the intensity at zero Q , related to the number of 
crosslinks per unit of volume.  
Equation 6.10 has been fitted to the experimental data, and the fitting curves are 
reported in figure 6.6 together with the experimental data. From the least square 
analysis the average mesh size, x  has been extracted and reported in table 6.3.  
 
Crosslink percentage ( )nmx  
1% 223±5 
10% 94±6 
Table 6.3: Mesh size x  obtained for HA hydrogels at different crosslinks percentage,  
in D2O, estimated from the fitting of equation 6.10. 
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Figure 6.6: Scattering intensities ( )I Q  
without crosslinks, ( ) 1% and ( ) 10% of crosslinks. Lines correspond to fitting of 
equation 6.10 to experimental data. 
 
 
As it can be observed, the crosslinks appear to compact the network, being the mesh 
size reduced of a factor 2 when their number is increased from 1% to 10%. 
 
6.3.4 In vitro degradation properties 
 
In order to evaluate hydrogels degradation, in vitro tests were performed. In figures 6.7a 
and 6.7b the degradation test results were reported. In figure 6.7a a comparison between 
the elastic modulus spectra evaluated at different degradation times, for the sample 
characterized by a HA concentration of 5% and a HA/DVS weight ratio of 5:1, was 
shown. From the results, it can be noticed that, at any frequency, G’ decreases with the 
increase of degradation time, meaning that in presence of HAase, the degradation 
occurs. 
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Figure 6.7 b 
Figure 6.7: In vitro degradation results: fig 6.7 a) the comparison of between the elastic 
modulus spectra evaluated at different degradation time (0, 3, 9, 16, 24 h); fig. 6.7 b) 
The evaluation of the percentage G’/G’o in function of time. 
 
The evaluation of the ratio G’/G’0 at frequency 0.1Hz in function of time, for an 
example sample, was reported in figure 6.7b; in particular this figure shows a 
degradation curve and a control curve, where the degradation curve indicates a 
quantitative evaluation of the percentage of degradation for each time, and the control 
curve shows that in absence of HAase, no degradation was observed. For this sample 
after 24 h of incubation, the percentage of degradation level is about 70%. 
Table 6.2 shows a summary of degradation tests in which the degradation percentage for 
each sample after 24 h of incubation was reported. It can be noticed that by increasing 
HA concentration of the hydrogel from 5% to 6%, the percentage of degradation level 
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decreases; keeping constant HA concentration and decreasing the HA/DVS weight 
ratio, the hydrogel shown a decreasing of the percentage of degradation level up to 35%. 
 
6.3.5 Biological properties 
6.3.5.1 In vitro study  
The direct cytotoxicity evaluation results on bulk hydrogels were shown in figure 6.8. In 
this graph, the percentage difference in reduction of Alamar Blue between hydrogels 
and control versus time was reported. The vitality of cells in contact with hydrogels is in 
the range 70 - 90% compared to negative control, after 24 hours. After 4 days of contact 
the vitality of the samples increases up to 100- 120%. The assay was stopped at 4 day 
because the cell proliferation was terminated by contact inhibition. 
In order to evaluate the proliferation of cells, the results of the PICO green test were 
reported in fig. 6.9 and expressed as the number of cells alive on the hydrogels after 1 
and 4 days. 
From fig.6.8-6.9 it can be concluded that the vitality and proliferation of cells placed in 
contact with the hydrogel is greater than control cells. This behaviour was shown for 
both HA concentrations, 5% and 6%, and for all considered HA/DVS weight ratio, 
2.5:1, 5:1, 8:1. The in vitro tests demonstrate that the hydrogels considered here show a 
good cellular response and the presence of DVS is not cytotoxic to cells.  
 
 
Chapter 6: Hyaluronic Acid Based Hydrogels For Regenerative Medicine Applications 
152 
 
 
Figure 6.8: Vitality tests: percentage of reduction of Alamar Blue between hydrogel 
and controls. The hydrogels are characterized by different HA concentrations (5% and 
6%) and different HA/DVS weight ratio (2.5:1, 5:1, 8:1). 
 
 
 
 
Figure 6.9: Proliferation tests after 1 and 4 days; the hydrogels are characterized by 
different HA concentrations (5% and 6%) and different HA/DVS weight ratio (2.5:1, 
5:1, 8:1). 
 
6.3.5.2 Stem cells differentiation 
 
The stem cell differentiation was evaluated by the determination of the ratio between 
the quantity of ALP and the quantity of DNA after that the cells were placed in contact 
with the hydrogels for 7, 14 and 21 days. The results were reported in table 6.4.  
From the biological results it can be noticed that for all samples the trend of ALP 
ng/DNA ng is the same: the values of ALP ng/DNA ng present a peak after 14 days that 
the mesenchimal stem cells were put in contact with the hydrogels.  
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Starting  
HA concentration 
HA/DVS 
Weight ratio 
ALP ng/DNA ng 
7days  
ALP ng/DNA ng 
14days  
ALP ng/DNA ng 
21days  
6% 2.5:1 
 
9.85 
 
 
14.53 
 
 
5.45 
 
6% 5:1 
 
7.56 
 
 
13.52 
 
 
3.3 
 
6% 8:1 
 
10.01 
 
 
15.33 
 
 
5.22 
 
5% 2.5:1 
 
7.68 
 
 
9.25 
 
 
4.05 
 
5% 5:1 
 
6.42 
 
 
7.52 
 
 
2.71 
 
5% 8:1 
 
8.31 
 
 
9.82 
 
 
3.02 
 
MSC VI (CTR)  
 
6.51 
 
 
8.25 
 
 
2.45 
 
Table 6.4: Biological properties in presence of osteogenic medium 
 
Varying the starting HA concentration, the biological properties change. In particular 
for any weight ratio the values of ALP ng/DNA ng, when the HA concentration is 6%, 
are higher than that when the HA concentration is 5%. So the presence of HA influences 
positively the activity of the cells.  
6.3.5.3 In vivo study 
From in vivo study it results that there was a comparable body weight gain for all the rat 
groups, no evidence of erythema or inflammation around HA hydrogels (figures 6.10 -
6.11) in any groups and slight swelling of the gel implant following injection.  
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Figure 6.10: visual observation 4 days after the injection of a moderately crosslinked 
HA implant 
 
 
Figure 6.11: Removal of moderately crosslinked HA hydrogel at day 21 
 
Residence time of the hydrogel is a function of the crosslinking degree. Non-modified 
HA is resorbed 1 day after injection; crosslinked HA hydrogels at HA/DVS w.r. of 5:1 
and HA/DVS w.r. of 8:1 are still present at the injection site at day 21 (figure 6.12).  
The remarkable difference in the residence time between non modified HA and HA 
crossliked hydrogels demonstrated that the chemical crosslinking was an effective way 
to increase the stability against enzymatic degradation of HA. 
 
 
Figure 6.12: Residence time for non modified HA, crosslinked HA hydrogels at 
HA/DVS w.r. of 5:1 and HA/DVS w.r. of 8:1 
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6.4 CONCLUSIONS 
 
HA-DVS crosslinked hydrogels based on a simple, reproducible and safe process that 
does not employ any organic solvents, were developed. Owing to an effective 
purification step, the resulting transparent and homogeneous hydrogels do not contain 
any detectable residual crosslinking agent and are easier to inject through a fine needle. 
These hydrogels exhibit a rheological behavior typical of a strong gel and show 
improved viscoelastic properties by increasing HA concentration and decreasing 
HA/DVS weight ratio. Furthermore it was demonstrated that processes such as 
sterilization and extrusion through clinical needles do not imply significant alteration of 
viscoelastic properties. From the SANS tests it resulted that the crosslinks appear to 
compact the network, being a reduction of the mesh size by increasing the crosslinker 
amount. In vitro and in vivo HA hydrogel degradation tests demonstrated that these new 
hydrogels show a good stability against enzymatic degradation, that increases by 
increasing HA concentration and decreasing HA/DVS weight ratio. Finally the 
hydrogels show a good biocompatibility confirmed by in vitro and in vivo tests.  
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CHAPTER 7 
 
Summary and outlook 
 
7.1 Summary 
 
This project was aimed to provide biocompatible hyaluronic acid (HA) based systems 
for applications in regenerative medicine and drug delivery. 
The choice of HA as starting material for the production of advanced biomaterials was 
due to the fact that it have attracted a great deal of interest among the researchers for its 
peculiar properties particularly suitable for the preparation of interesting biocompatible 
systems (see Chapter 1). 
In particular in the first part of this thesis HA coated biodegradable nanoparticles as 
novel drug carriers for tumor targeting were developed. Nanoparticles were prepared by 
a single emulsion technique and shown a spherical shape and a size ranging from 170 to 
300 nm (see Chapter 2). The amphiphilic nature of these nanostructured devices, 
characterized by a inner hydrophobic core and a hydrophilic shell, allowed to obtain a 
drug encapsulation efficiency of 61.2% and in vitro sustained Irinotecan release up to 24 
days (see Chapter 3). 
In the second part of this thesis novel self-associative nanostructured soft carriers based 
on an amphiphilic hyaluronic acid derivative were developed. The new syntetized 
amphiphilic HA derivative is an octenyl succinic anhydride (OSA) modified HA, 
obtained through a simple reaction in an aqueous medium involving exclusively HA 
hydroxyl groups. This derivative was able to self assemble into micelles characterized 
by a spherical shape and diameter around 100 nm. In the perspective of using these 
novel devices as viscosupplementation products, the rheological properties were 
evaluated and it was demonstrated that OSA-HA solutions could be suitable tools to be 
used in viscosupplentation therapy, exhibiting a viscoelastic behavior similar to that of 
synovial fluid (see Chapter 4). Furthermore thanks to the presence of hydrophobic 
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domains along the molecule backbone, these nanosized structures were able to load a 
hydrophobic drug, triamncinolone, usually used for the treatment of joint diseases, and 
release it with a controlled kinetic (see Chapter 5). 
In the third part of this thesis stable structures at macroscale obtained crosslinking HA 
molecules to form injectable hydrogels for regenerative applications were developed. 
HA hydrogels, produced crosslinking HA molecules with divinyl sulfone (DVS), were 
based on a simple, reproducible and safe process that does not employ any organic 
solvents. Owing to an effective purification step, the resulting homogeneous hydrogels 
do not contain any detectable residual crosslinking agent and are easier to inject through 
a fine needle. HA hydrogels were characterized in terms of their viscoelastic and 
network structural properties. They exhibit a rheological behavior typical of a strong gel 
and show improved viscoelastic properties by increasing HA concentration and 
decreasing HA/DVS weight ratio. Furthermore it was demonstrated that processes, such 
as sterilization and extrusion through clinical needles, do not imply significant alteration 
of viscoelastic properties. In vitro and in vivo HA hydrogel degradation tests 
demonstrated that these new hydrogels show a good stability against enzymatic 
degradation, that increases by increasing HA concentration and decreasing HA/DVS 
weight ratio. Furthermore in vitro and in vivo studies demonstrated that these materials 
are biocompatible and non-toxic, and show a long in vivo residence time (see Chapter 
6). 
 
7.2 Future work 
 
In the perspective of using HA coated biodegradable nanoparticles for concrete 
applications in cancer therapy and OSA-HA nanogels for the treatment of joint 
diseases, it could be necessary to obtain a better control of their polydispersity. 
Furthermore future work will be devoted to confirm the validity of these systems with 
in vitro and in vivo studies. 
Finally the HA based hydrogels will be further investigated for various drug delivery 
and tissue engineering applications. 
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